



# Guidelines for the diagnosis and treatment of neurally mediated syncope in children and adolescents (revised 2024)

Cheng Wang<sup>1</sup> · Ying Liao<sup>2</sup> · Shuo Wang<sup>3</sup> · Hong Tian<sup>4</sup> · Min Huang<sup>5</sup> · Xiang-Yu Dong<sup>6</sup> · Lin Shi<sup>7</sup> · Ya-Qi Li<sup>7</sup> · Jing-Hui Sun<sup>8</sup> · Jun-Bao Du<sup>2</sup> · Hong-Fang Jin<sup>2,9</sup> · Chinese Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association; Committee of Pediatric Syncope, College of Pediatricians, Chinese Medical Doctor Association; Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association; Committee of Pediatric Cardiology, College of Cardiovascular Physicians, Chinese Medical Doctor Association

Received: 18 April 2024 / Accepted: 17 May 2024  
© The Author(s) 2024

## Abstract

**Background** Significant progress has been made in the diagnosis and treatment of pediatric syncope since the publication of the “2018 Chinese Pediatric Cardiology Society (CPCS) guideline for diagnosis and treatment of syncope in children and adolescents” (“2018 Edition Guidelines”). Therefore, we have revised and updated it to assist pediatricians in effectively managing children with syncope.

**Data sources** According to the “2018 Edition Guidelines”, the expert groups collected clinical evidence, evaluated preliminary recommendations, and then organized open-ended discussions to form the recommendations. This guideline was developed by reviewing the literature and studies in databases including PubMed, Cochrane, EMBASE, China Biomedical Database, and Chinese Journal Full-text Database up to April 2024. Search terms included “syncope”, “children”, “adolescents”, “diagnosis”, and “treatment.”

**Results** The guidelines were based on the latest global research progress and were evidence-based. The classification of syncope etiology, diagnostic procedures, postural tests, such as the active standing test, head-up tilt test, and active sitting test, clinical diagnosis, and individualized treatment for neurally mediated syncope in pediatric population were included.

**Conclusions** The guidelines were updated based on the latest literature. The concepts of sitting tachycardia syndrome and sitting hypertension were introduced and the comorbidities of neurally mediated syncope were emphasized. Some biomarkers used for individualized treatment were underlined. Specific suggestions were put forward for non-pharmacological therapies as well as the follow-up process. The new guidelines will provide comprehensive guidance and reference for the diagnosis and treatment of neurally mediated syncope in children and adolescents.

**Keywords** Adolescents · Children · Diagnosis · Neurally mediated syncope · Treatment

---

The members of the group Chinese Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association; Committee of Pediatric Syncope, College of Pediatricians, Chinese Medical Doctor Association; Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association; Committee of Pediatric Cardiology, College of Cardiovascular Physicians, Chinese Medical Doctor Association are listed in Acknowledgements.

---

Extended author information available on the last page of the article

## Introduction

Syncope is a transient loss of consciousness (TLOC) and inability to maintain the posture caused by transient global cerebral hypoperfusion. It is characterized by a rapid onset, short duration, and spontaneous complete recovery [1–4] (I; C). Syncope, a common disorder in children and adolescents, has an incidence of 17.37% [5], with a higher occurrence in girls than in boys [6] (IIa; B). It accounts for 1%–2% of visits to the emergency department [1]. The pathogenesis, etiology, diagnosis, and treatment of pediatric syncope differ from those in adults. Recurrent syncope can seriously impact the physical and mental health, learning abilities, and quality of life of

affected children [7, 8] (IIa; A). In some cases, syncope with cardiogenic causes can even pose a risk of sudden death. From 2015 to 2018, the Heart Rhythm Society, the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, the Canadian Cardiovascular Society, the Canadian Pediatric Cardiology Association, and the European Society of Cardiology successively published guidelines or society position statements on the diagnosis and management of syncope and related syndromes [2, 9–11] (I; C). In 2018, professional societies including the Chinese Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association; Committee of Pediatric Syncope, College of Pediatricians, Chinese Medical Doctor Association; Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association; Committee of Pediatric Cardiology, College of Cardiovascular Physicians, Chinese Medical Doctor Association released the "2018 Chinese Pediatric Cardiology Society (CPCS) guidelines for diagnosis and treatment of syncope in children and adolescents" (hereafter referred to as the "2018 Edition Guidelines") [1] to promote the standardized diagnosis and treatment of syncope in children and adolescents. In recent years, significant progress has been made in the clinical diagnosis and treatment of syncope, especially neurally mediated syncope (NMS) in children and adolescents, including the etiological classification of syncope, diagnostic procedures, posture tests, such as the active standing test, the head-up tilt test (HUTT), as well as the active sitting test, clinical diagnosis, and individualized treatment [12–25]. The "Guidelines for the diagnosis and treatment of neurally-mediated syncope in children and adolescents (revised 2024)" were developed based on

the "2018 Edition Guidelines" and followed the latest global research advances. However, more large-scale, multi-center, randomized controlled clinical studies are needed to provide a higher level of evidence for the treatment of NMS in children and adolescents [26].

## Classes of recommendations and levels of evidence to manage pediatric syncope

The classes of recommendations and levels of evidence for the management of pediatric syncope were weighed and graded based on predefined scales (Tables 1, 2) [1, 2] (I; C).

## The underlying diseases of syncope in children and adolescents

The causes of syncope in children and adolescents include NMS, cardiac syncope (CS), and unexplained syncope (UPS) [1]. NMS is the most common cause accounting for 70%–80%, CS accounts for 2%–3%, and UPS accounts for about 20% [7] (I; C). The causes of syncope in children and adolescents are classified and listed in Table 3.

NMS in children and adolescents is characterized by syncopal attacks caused by abnormal reflex regulation or dysfunction of the autonomic nervous system, mainly referring to vasovagal syncope (VVS) and postural orthostatic tachycardia syndrome (POTS), which accounts for about 95% of NMS [4, 27–30] (IIa; B). Breath-holding spells in infancy may be a specific type

**Table 1** Classes of recommendations for the management of pediatric syncope

Classes of recommendations	Definition	Suggested wording to use
Class I	Evidence and/or general agreement that the given treatment or procedure is beneficial, useful and effective	Is recommended/indicated
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure	
Class IIa	Weight of evidence/opinion favors the usefulness/efficacy	Should be considered
Class IIb	Usefulness/efficacy is less well established by evidence/opinion	May be considered
Class III	Evidence or general agreement that the given treatment or procedure is not useful/effective and in some cases may be harmful	Is not recommended

**Table 2** Levels of evidence for the management of pediatric syncope

Level of evidence	Source of evidence
A	Data derived from multiple randomized clinical trials or meta-analyses
B	Data derived from a single randomized clinical trial or large non-randomized studies
C	Consensus of opinion of experts and/or small studies, retrospective studies, registries

**Table 3** Classification of syncope in children and adolescents

Classes	Underlying diseases and associated syndrome
Neurally mediated syncope	Vasovagal syncope Vasoinhibitory type Cardioinhibitory type Mixed type Postural orthostatic tachycardia syndrome Orthostatic hypotension Orthostatic hypertension Sitting tachycardia syndrome Sitting hypertension Situational syncope Carotid sinus syndrome
Cardiac syncope	Arrhythmia Structural cardiac diseases, including cardiomyopathy, etc.
Unexplained syncope	

of NMS [31, 32] (I; C). In children and adolescents, NMS is often associated with comorbidities [33, 34]. Nearly 30%–40% of children and adolescents with VVS and/or POTS generally also have allergic diseases [35] (IIa; B), and some may also be associated with coagulation disorders [36], but patent foramen ovale may not increase the risk of pediatric syncope [37] (IIa; B). Other common comorbidities include migraines, mental disorders, sleeping disorders, hyperventilation syndrome, chronic fatigue syndrome, joint hypermobility syndrome, and gastrointestinal disorders. Comorbidities may increase the complexity of diagnosis and treatment [38] (IIa; B).

CS is mainly caused by abnormal structure or rhythm of the heart. Although CS is a relatively rare cause of pediatric syncope, it is associated with a high risk of sudden death and needs to be diagnosed as early as possible [39] (IIa; B).

Other causes of TLOC [7, 40] (IIa; A), including epileptic seizures, metabolic disorders (e.g., hypoglycemia and hypoxemia), poisoning, and psychological pseudosyncope (PPS) [41–43] (IIa; B), can sometimes be misdiagnosed as syncope. These disorders do not produce transient cerebral hypoperfusion, and thus, should be strictly differentiated from syncope.

## Diagnosis

### Diagnostic procedures for pediatric syncope

As shown in Fig. 1, the diagnostic procedures comprise three steps [44] (IIa; B). In the first step, after medical history taking, physical examination, supine and upright blood pressure (BP) measurement, and supine and upright electrocardiogram (ECG) recording, the patients can be divided into three groups: definite diagnosis, suggestive diagnosis, and UPS [1].

### Definitive diagnosis

POTS, orthostatic hypotension (OH), orthostatic hypertension (OHT) [45, 46] (IIa; A), sitting tachycardia syndrome (STS), and sitting hypertension (SHT) [47, 48] (IIa; B) can be indicated by the history of symptoms of orthostatic intolerance (OI) or sitting intolerance. A diagnosis can be confirmed when patients with typical symptoms have a normal ECG and a positive result in an active standing test, HUTT, or active sitting test [49–56] (IIa; B). Situational syncope (SS) is defined as syncope in specific situations, such as micturition, defecation, bathing, swallowing, cough, post-dinner, singing, teeth brushing, and hair grooming [57, 58] (IIa; B). Drug-induced syncope (determined through medication history) can be diagnosed by typical history.


### Suggestive diagnosis

The patients with suggestive diagnosis after the first step, as seen in Fig. 1, need further laboratory investigations in step 2. In step 2, cardiomyopathy, pulmonary hypertension, cyanotic congenital heart disease, and some types of arrhythmias can be suspected according to the clues from history, physical examination, and ECG findings. For example, onset in infancy or early childhood, exercise-induced events [59] (IIa; B), family history of genetic heart disease or sudden death, and abnormal ECG findings can suggest CS, with the strongest clues provided by exercise-induced syncope and abnormal ECG findings [60, 61]. For such patients, further examinations are needed to ensure the diagnosis, such as repetitive ECG, Holter ECG, implanted loop recorder (ILR) [62] (IIa; B), exercise test, intracardial electrophysiology, angiography, cardiovascular imaging, screening of metabolic disorder or genetic tests, based on the specific situation [46, 63] (IIa; B).

### Unexplained diagnosis

In step 3, for patients whose diagnosis cannot be confirmed or indicated by detailed medical history, physical examination, supine BP, and ECG measurements [48] (IIa; A), if the symptoms occur more than once and the characteristics of the attacks suggest NMS, postural tests such as the active standing test, HUTT [9, 64–66] (IIa; B), and active sitting test [47, 48] (IIa; A) can be performed. These tests may help in diagnosing NMS and determining its hemodynamic type.

If a definite diagnosis cannot be achieved even after the above steps are taken, a re-evaluation is needed. This includes history-retaking, physical re-examination, and further laboratory examinations. Moreover, assessment by associated specialists such as neurologists or psychiatrists should be considered when necessary.



**Fig. 1** Diagnostic procedure for pediatric syncope. *ECG* electrocardiogram, *SS* situational syncope, *POTS* postural orthostatic tachycardia syndrome, *OH* orthostatic hypotension, *OHT* orthostatic hypertension, *STS* sitting tachycardia syndrome, *SHT* sitting hypertension, *CHD* congenital heart disease, *HUTT* head-up tilt test, *VVS* vasovagal syncope, *VVS-VI* vasovagal syncope vaso-inhibitory type, *VVS-CI* vasovagal syncope cardioinhibitory type, *VVS-M* vasovagal syncope mixed type. <sup>a</sup>For children with normal physical examination and normal routine ECG findings, ECG is generally not helpful in determining possible reasons. For children with possible structural heart defects after medical history, physical examination, and routine ECG. ECG is a screening tool to detect abnormal cardiac structures or functions; <sup>b</sup>Holter ECG is a common test to determine the cause of syncope. However, because syncope is unpredictable, regular monitoring for only 24 hours makes it difficult to confirm or thoroughly rule out the association between arrhythmia and syncope. When diagnosing the cause of syncope, comprehensive judgment should be made together with history-taking and other tests. The

possible reasons include asymptomatic sinus bradycardia, atrioventricular block, and endless supraventricular or ventricular tachycardia. For children with recurrent syncope, Holter ECG and ILR are important for diagnosis and differential diagnosis. For children with syncope induced by sports and emotions, an exercise test should be performed to detect potential arrhythmias. During exercise trials, first aid is prepared as a precaution; <sup>c</sup>for patients with suspected sick sinus syndrome, atrioventricular conduction abnormalities, and/or all ventricular and supraventricular arrhythmias, the diagnosis can be confirmed by cardiac electrophysiological examination when necessary; <sup>d</sup>for patients with suspected pulmonary hypertension or coronary heart disease, although ECG cannot clarify the diagnosis, cardiac catheterization and angiography may be considered; <sup>e</sup>for patients with suspected hereditary disease, such as ion channel diseases, cardiomyopathy, or genetic metabolic diseases, and for those with a family history of genetic heart disease or sudden death, the diagnosis may be confirmed by metabolic disorder screening and/or genetic tests

## Methodology of postural tests

### Active standing test

The active standing test can be performed to screen for underlying causes of OI in children. It has no absolute contraindications.

**The protocol** First, the children are asked to lay supine for 10–30 minutes to obtain supine heart rate (HR), BP, and

ECG recordings. Then, the children are told to actively stand for another 10 minutes, simultaneously monitoring the above parameters [65–67] (IIa; A).

**Clinical comments** During the active standing test, the children should be closely observed to determine whether they have presyncope symptoms or even syncope, and the test can help diagnose POTS [66, 67], OH [66, 68], or OHT [66, 69] (IIa; B). Here, the presyncope consists of symptoms including dizziness, headache, chest tightness, palpitations,

nausea, vomiting, pallor, cold sweats, blurred vision, hearing loss, abdominal pain, and variable degrees of altered consciousness without complete loss of consciousness. HR, BP, and ECG are monitored in the supine position. When the ECG electrode does not move, observations of OI, HR, BP, and ECG are made for 10 minutes after assuming an upright position. Changes in HR and ECG waveforms between supine and upright positions are compared. Significant changes in T-wave morphology of decubitus and upright ECG help judge autonomic nervous function [70, 71] (IIa; B). In patients with clinical manifestations of OI but with a negative active standing test result, the HUTT could be considered if they do not have contraindications. Criteria for the positive response for POTS, OH and OHT refer to relevant section of “Criteria for the positive response of active standing test and head-up tilt test”.

### Head-up tilt test

**Indications and contraindications** Indications for the HUTT include (1) to clinically confirm a suspected NMS, which cannot be diagnosed by other tests [1, 72] (I; C) and (2) to make a differential diagnosis with pseudosyncope [42, 73] (IIa; B). Contraindications for the HUTT are (1) known aortic stenosis or left ventricular outflow tract obstruction; (2) severe mitral stenosis; (3) definite pulmonary hypertension or right ventricular outflow tract obstruction; (4) serious stenosis in the proximal coronary artery; (5) definite severe cerebrovascular diseases; and (6) syncope caused by definite arrhythmia [1] (I; C).

**Preparation for the head-up tilt test** The test environment must be quiet with dim light, a comfortable room temperature, and no distractions [1] (I; C). Medicines such as nitroglycerin tablets for sublingual nitroglycerin-provoked HUTT, adrenaline, atropine, and first aid equipment, including an oxygen inhalation device and defibrillator, should be prepared.

The tilt table should have supported foot pedals, with fences on both sides and fixed belts for the chest and knee joints to avoid knee flexion and falling. The electric table board should be well-controlled and move smoothly so that the table can be tilted to a certain angle from the horizontal position and return to a horizontal position from any tilted angle [74] (IIa; B).

The operators should cautiously observe the details of the patient’s manifestations suggesting syncope or presyncope attacks and must be familiar with the rules to stop the test and rescue program of the HUTT [75] (I; C). The detailed procedure of the HUTT should be explained to children and their legal guardians/parents to relieve their anxiety and obtain their cooperation during the whole test [1] (I; C).

**Informed consent:** the HUTT has certain potential risks, such as a fainting attack or significant hemodynamic changes such as cardiac asystole [76–80] (IIa; B). Therefore, detailed instructions and risks should be described to children and their legal guardians/parents, and signed informed consent should be obtained before the test [81] (IIa; B).

**Preparation of the pediatric patient:** any vasoactive drugs should be discontinued for at least five half-lives. Food and beverages, such as coffee, that might affect autonomic nervous system functions should be avoided for at least 24 hours before the test. Children should fast for at least 4 hours before the test. The test should be performed in the morning [67, 82] (IIa; B) without the presence of unrelated persons [72].

**Steps of the head-up tilt test** Basic HUTT (BHUT): children should first lie on the tilt bed in a horizontal position for around 10–30 minutes with fixed bands to avoid buckling of knee joints. HR, BP, and ECG recordings are taken during this period. Then, the bed is tilted upward at an angle of 60° and HR, BP, and ECG are simultaneously monitored. The test must be stopped, and the children should be placed in the supine position (from the upright position) when the children show a positive response (see section “Criteria for the positive response”) or have completed the whole 45 minutes process, or if the patient requires stopping for any reason [83, 84] (IIa; B).

Sublingual nitroglycerin-provoked HUTT (SNHUT): if no positive response has been developed during the BHUT, the children are suggested to undergo a SNHUT, in the same position for a further 20 minutes after sublingual administration of nitroglycerin at a dose of 4–6 µg/kg (maximum ≤ 300 µg) [85] (IIa; B). The endpoint of the test is a positive response or completion of the process. After the administration of the medicine as mentioned above, HR, BP, ECG, and clinical performance should be carefully recorded simultaneously [86, 87] (IIa; A).

**Criteria for the positive response of active standing test and head-up tilt test** Vasovagal syncope: syncopal episodes or presyncope symptoms together with any of the following responses in the HUTT are considered positive responses: (1) systolic BP (SBP) ≤ 80 mmHg (1 mmHg = 0.133 kPa) or diastolic BP (DBP) ≤ 50 mmHg, or mean pressure decrease ≥ 25%; (2) HR < 75 bpm for children aged 4 to 6 years, < 65 bpm for children aged > 6 to 8 years, and < 60 bpm for children and adolescents > 8 years; (3) ECG showing sinus arrest or junctional escape rhythm; (4) atrioventricular block (II or III degree) or cardiac arrest ≥ 3 seconds. The responses are classified as VVS vasoinhibitory type (VVS-VI), VVS cardioinhibitory type (VVS-CI), or VVS mixed type (VVS-M). VVS-VI is characterized by a significant decrease in BP without an obvious decrease in

HR, VVS-CI by a marked decrease in HR without a marked decrease in BP, and VVS-M by both an HR and BP decrease [1, 45, 88, 89] (IIa; A). Malignant VVS is characterized by cardiac arrest lasting more than 3 seconds during a syncope episode or the test [90, 91] (IIa; B).

**Postural orthostatic tachycardia syndrome:** the diagnosis of POTS is influenced by the circadian rhythm [92, 93] (IIa; B). It was reported that, during the active standing test for children, the difference in HR between supine and upright positions is more significant in the morning when compared with that in the afternoon or the evening [67] (IIa; B). Therefore, it is recommended to take a posture test in the morning (IIa; B). During the upright position of the active standing test or the initial 10 minutes of HUTT, a positive response for POTS is defined as a HR increase of  $\geq 40$  bpm or a maximum upright HR  $\geq 130$  bpm (in children aged 6 to 12 years old) or  $\geq 125$  bpm (in adolescents over 12 years older but under 18) [66, 87] (IIa; A). However, all positive responses should exclude significant BP decrease (where SBP decreases by  $> 20$  mmHg and/or DBP decreases by  $> 10$  mmHg).

**Orthostatic hypotension:** for classic OH, the supine BP is normal. During the initial 3 minutes of the active standing test or HUTT, SBP decreases at least by 20 mmHg and/or DBP decreases at least by 10 mmHg [1, 68] (I; C). The initial OH is defined by a transient BP decrease occurring within 15 seconds after standing.

**Orthostatic hypertension:** supine BP is normal and during the initial 3 minutes of the active standing test or HUTT, SBP increases by  $\geq 20$  mmHg and/or DBP increases by  $\geq 25$  mmHg (in children aged 6–12 years) or  $\geq 20$  mmHg (in adolescents aged 12–18 years) from supine to upright position; or upright BP is  $\geq 130/90$  mmHg (in children aged 6–12 years) or  $\geq 140/90$  mmHg (in adolescents aged 12–18 years) without an obvious change in HR [66, 94, 95] (IIa; B).

**Characteristics of the head-up tilt test in children** The autonomic nervous system of children is continuously developing and maturing, rendering it more unstable compared to that of adults. As a result, the hemodynamic parameters of the HUTT change more rapidly and abruptly, leading to positive responses appearing quite early in children. Additionally, children tend to cooperate less during the test than adults. Therefore, it is important to closely monitor and obtain the cooperation of children as much as possible during the HUTT. In most cases, children with POTS are more likely to demonstrate symptoms of OI than those with OH [96] (IIa; B). ECG changes such as sinus arrhythmia and sinus bradycardia in HUTT can predict an increased probability of positive responses [77] (IIa; B). Abnormal T-wave patterns, T-wave apex to T-wave end interval dispersion (Tped), and prolongation of the QT interval during

the HUTT are useful in identifying children with VVS, who are more susceptible to ventricular arrhythmias with a latent risk of long QT syndrome [97] (IIa; B).

**Safety issues of the head-up tilt test** The HUTT should be performed following the indications and operation protocols to guarantee safety. The HUTT may induce syncope or presyncope symptoms leading to adverse events or complications such as arrhythmias [77], transient aphasia [78], convulsions [79], and fear [98] (IIa; B). However, the HUTT is generally considered safe when performed in accordance with the recommendations of the standard HUTT protocol and when syncope caused by organic heart diseases is fully excluded [72, 76, 81] (IIa; B). During the HUTT, long RR intervals  $> 2$  seconds in ECGs are not rare. Returning the patient to the recumbent position in time can promote recovery in consciousness. For children aged 3–18 years, the HUTT demonstrates high specificity, and severe HUTT-related complications have been rarely reported in recent studies [76, 99, 100] (IIa; B).

#### Active sitting test

The operation is simple and relatively safe, serving as a preliminary screening tool to identify the basic etiology in children and adolescents presenting symptoms of sitting intolerance such as dizziness, blurred vision, headache, chest tightness, nausea, abdominal pain, numbness and sweating when sitting, without clear contraindications [47] (IIa; B).

**The protocol** After the children empty their bladder, the active sitting test is carried out in a quiet and comfortable room. The children are first asked to be in a supine position for 10 minutes and then in a sitting position for 10 minutes. Changes in HR and BP during sitting, as well as whether dizziness, pale face, fatigue, blurred vision, chest tightness, palpitations, abdominal pain, nausea, vomiting, and other symptoms of sitting intolerance occur during the test are dynamically observed and recorded. If the children are unable to complete the test, the test is terminated prematurely. STS and SHT can be diagnosed by an active sitting test [47, 101] (IIa; B).

**Criteria for the positive response of active sitting test** Sitting tachycardia syndrome: symptoms of sitting intolerance appear within 10 minutes after the change from a supine to a sitting position, and an increase in HR by  $\geq 25$  bpm after 3 minutes of sitting suggests STS [47, 102, 103] (IIa; B).

Sitting hypertension: symptoms of sitting intolerance occur within 10 minutes after the transition from a supine to a sitting position, and SBP elevation by  $\geq 20$  mmHg and/or DBP elevation by  $\geq 20$  mmHg within 3 minutes of sitting suggest SHT [47, 102, 103] (IIa; B).

## Diagnostic criteria of neurally mediated syncope and associated syndromes

A detailed medical history can provide valuable information for diagnosis [60, 104] (IIa; A), and adherence to diagnostic guidelines may facilitate in correctly diagnosing patients experiencing syncope while avoiding unnecessary medical tests [39, 105–107]. Syncope is one of the common clinical manifestations of NMS in children and adolescents, although some cases can start with non-syncope symptoms, such as dizziness [108], tightness or pain in the chest [109], sigh or hyperventilation [110], palpitations [111], and abdominal pain [112, 113] (IIa; B).

### Vasovagal syncope

The diagnostic criteria of VVS are as follows: (1) in most patients, it is associated with predisposing factors, such as persistent standing or sudden changes in body position (body position quickly changing to an upright position from supine or sitting or squatting), emotional stress, and crowded or stuffy environment; (2) a history of syncope is confirmed; (3) it features a positive hemodynamic response during a HUTT (see section “Criteria for the positive response of active standing test and head-up tilt test”); and (4) other causes of TLOC should be excluded [1, 114, 115] (IIa; B).

### Postural orthostatic tachycardia syndrome

The diagnostic criteria of POTS are as follows: (1) the course of the disease is usually > 1 month and is often associated with most of the above-mentioned inducing factors (as seen in VVS). There are also some risk factors such as high basal HR in a supine position (a 10 bpm increase in HR in a supine position indicates an increased risk of POTS by 1.58 times), low water intake (water intake of children < 800 mL/day increases the risk of POTS by 3.88 times), insufficient sleep duration (i.e., children sleeping < 8 hours/day results in a 5.91 times increase in the risk of POTS) [116] (IIa; A); (2) OI symptoms include the main manifestations, such as dizziness, headache, fatigue, blurred vision, chest tightness, palpitations, hand tremors, intolerance to movement, and even syncope especially in an upright position [49, 117] (IIa; B); (3) a positive HUTT or active standing test result indicating POTS is required (see section “Criteria for the positive response of active standing test and head-up tilt test”); and (4) other diseases that may cause similar symptoms should be excluded [65] (IIa; A).

### Orthostatic hypotension

The diagnostic criteria of OH are as follows: (1) it is often associated with most of the above-mentioned inducing

factors (as seen in VVS); (2) OI often occurs immediately after standing; (3) a positive HUTT or active standing test result is required (see Section “Criteria for the positive response of active standing test and head-up tilt test”); and (4) other diseases that cause similar symptoms should be excluded [68].

### Orthostatic hypertension

The diagnostic criteria of OHT are as follows: (1) it is associated with the above predisposing factors in most patients (as seen in VVS). Being overweight, defined as having a body mass index (BMI) above the 85th percentile for the same sex and age group, causes a 6.07 times increase in the risk of OHT, while obesity (BMI > 95th percentile) increases the risk of OHT by 7.48 times. Drinking less water (water intake < 800 mL/day) causes a 4.03 times increase in the risk of OHT. Increased sleep duration by 1 hour per night decreases the risk of OHT by 74.3% [118] (IIa; B); (2) it is often associated with OI during the upright position; (3) a positive HUTT or active standing test result is required (see section “Criteria for the positive response of active standing test and head-up tilt test”); and (4) other diseases that cause similar symptoms should be excluded [66, 94, 119] (IIa; B).

### Sitting tachycardia syndrome

The diagnostic criteria of STS are as follows: (1) it involves precipitating factors such as a sudden change in position (from supine to sitting), mental tension, stuffy environment, and insufficient sleep duration in most patients [48] (IIa; A); (2) the patients have symptoms of sitting intolerance, and syncope can also occur in severe cases; (3) the change of HR reaches the criteria for the positive response of active sitting test (see section “Criteria for the positive response of active sitting test”); and (4) other diseases that cause similar symptoms should be excluded [47, 48] (IIa; A).

### Sitting hypertension

The diagnostic criteria of SHT are as follows: (1) it involves many precipitating factors such as a sudden change in position (from supine to sitting), mental tension, stuffy environment, and insufficient sleep time in most patients; (2) the patients have symptoms of sitting intolerance, and syncope can also occur in severe cases; (3) the change of BP reaches the criteria for the positive response of active sitting test (see section “Criteria for the positive response of active sitting test”); and (4) other diseases that cause similar symptoms should be excluded [47, 48] (IIa; A).

## Situational syncope

SS is a type of reflex syncope, presupposed by special situations and directly related to relatively fixed triggers. Most SS episodes occur in the upright position and nearly half of the patients have positive responses to HUTT. SS includes micturition syncope, defecation syncope, cough syncope, swallowing syncope, and breath-holding spells according to different induced situations [57, 58] (IIa; B).

## Treatment

### Vasovagal syncope

Significant progress has been made in the individualized treatment of VVS [4, 120–125], and a common strategy to prevent the onset of VVS is non-pharmacological treatment based on lifestyle changes [28, 126] (IIa; B).

### Health education

After VVS is diagnosed, health education on the management of syncope, including basic knowledge and skills in self-protection, is required for patients and legal guardians/parents, which can help reduce episodes of syncope and the possible physical as well as psychological harm it causes to pediatric patients. A health education model using mind mapping can significantly improve the effectiveness of this education [127] (IIa; B).

**Trigger avoidance:** children with VVS and their legal guardians/parents are advised to recognize common triggers, such as prolonged standing, quick position changes from a prolonged supine or sitting or squatting position to an upright position, sudden stops after prolonged movement (e.g., after long-distance running), a crowded or stuffy environment, and emotional stress (e.g., nervousness caused by painful stimuli or a medical operation). Syncope may be more likely to occur under some special conditions such as vomiting, diarrhea, anemia, low iron stores, infection, menstruation, and the use of some drugs, such as diuretics, which can reduce blood volume or BP. When triggers cannot be completely avoided, more attention should be given to pediatric patients to prevent physical injury and psychological disorders associated with syncope [10] (I; C).

**Identification of presyncope symptoms and physical counter-pressure maneuvers:** when presyncope occurs, patients should adjust their position, such as changing to a sitting position or lying down, if possible. Most symptoms can be alleviated in a short time [128] (IIa; B).

Physical counter-pressure maneuvers may avoid or delay the syncope by increasing peripheral venous return, such as slight bending of the knees, contracting abdominal muscles or limb muscles (hands clasped, elbow flexion, legs crossed, and toes dorsiflexion) after prolonged standing [10, 129–131] (I; C).

**Maintaining psychological well-being:** recurrent syncope may adversely affect the psychological well-being of patients, seriously affecting their quality of life, and even causing PPS [42] (IIa; B). Therefore, legal guardians/parents and healthcare staff should pay attention to the mental health of the patients. Patients should be informed that this type of syncope usually has a favorable prognosis and should be approached with a positive mindset. Patients are encouraged to communicate with others to relieve psychological stress. Legal guardians/parents should be suggested to comfort and support their children. If necessary, special psychological counseling or therapy should be recommended [132, 133] (IIa; B).

**Appropriate physical exercise:** appropriate exercise is beneficial in increasing pump function of limb muscle in patients with VVS, which is important for recovery. Regular physical exercise plans and exercise without obvious discomfort are recommended. Additionally, children with VVS are advised to do physical exercise under supervision [131].

### Autonomic nervous function exercise

**Upright training (tilt training)** Patients are encouraged to stand upright against the wall with their feet approximately 15 cm away from the wall under supervision. The time for standing should be decided based on the tolerance and preference of the patient. Generally, the children may start from 5 minutes per session, twice daily, gradually increasing to 30 minutes per session [9] (I; C). Some biomarkers may help get a better effect of intervention from this measure [134–138] (IIa; B) (Table 4).

**Dry towel wiping** The forearms and both legs of the patient are recommended to be repeatedly wiped with a soft and dry towel. Five minutes is recommended for each part, twice a day [139] (I; C).

### Increase the intake of water and salt

Adequate daily water intake up to 30–50 mL/kg/day (no more than 1500–1700 mL) is recommended to achieve a clear urine color. Salt intake can be increased through additional salt intake in daily meals or regular drinking of oral rehydration salts (ORS) for at least two months, after which re-evaluation should be conducted for the



**Table 4** Biomarkers for predicting therapeutic outcomes in children and adolescents with vasovagal syncope

Biomarkers and cutoff values	Clinical significance
ECG acceleration index <26.77 [134]	Upright training (tilt training) may be recommended
Night-time DBP standard deviation <5.75 mmHg [137]	Upright training (tilt training) may be recommended
Night-time DBP variation coefficient <13.2% [137]	Upright training (tilt training) may be recommended
24-h urine adrenaline <5.53 µg [138]	Upright training (tilt training) may be recommended
Body mass index <18.9 kg/m <sup>2</sup> [144]	Oral rehydration salts may be recommended
24-h urine sodium <83 mmol/L [145]	Oral rehydration salts may be recommended
Flow-mediated vasodilation >8.85% [150]	Midodrine hydrochloride may be recommended
Plasma CGRP level >62.56 pg/mL [151]	Midodrine hydrochloride may be recommended
Serum uric acid <299 µmol/L [152]	Midodrine hydrochloride may be recommended
HR increases before positive response in HUTT compared to the supine HR >30 bpm [115]	Metoprolol may be recommended
24-h urinary norepinephrine >34.84 µg [155]	Metoprolol may be recommended
Baroreflex sensitivity >10 ms/mmHg [157]	Metoprolol may be recommended
LVEF >70.5% [159]	Metoprolol may be recommended
LVFS >38.5% [159]	Metoprolol may be recommended
Poincaré plot longitudinal/transverse axis ratio >2.7 [160]	Metoprolol may be recommended

ECG electrocardiogram, DBP diastolic blood pressure, CGRP calcitonin gene-related peptide, HR heart rate, HUTT head-up tilt test, LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening

patients [140–142] (IIa; B). In hot weather seasons, excessive sweating or fluid loss may occur and further increase of water and salt intake is needed. The combination of hemoglobin and BMI values can provide a reference for the selection of ORS [143] (IIa; B). Certain biomarkers can predict that ORS has a better effect on VVS [142, 144–146] (IIa; B) (Table 4). Additionally, ORS is especially suitable for children with VVS-VI [147] (IIa; B), but is not recommended for patients with hypertension, kidney disease, or heart failure [1] (I; C).

### Pharmacological intervention

**Indications** Children with recurrent syncope (more than twice every 6 months or more than three times per year), with risk of injury, and poor response to non-pharmacological therapy may be considered for pharmacological therapy [10, 148] (I; C).

**Midodrine hydrochloride** The initial dose ranges from 1.25 to 2.5 mg/time, once or twice daily. After 2–4 weeks, it can be increased to 2.5 mg/time, three times daily. During medication, the supine BP should be monitored; the dose should be reduced or discontinued when the supine BP increases significantly (above the 95th percentile of BP) [149] (IIa; B). Some biomarkers can predict that midodrine hydrochloride may lead to better outcomes of VVS cases [150–152] (IIa; B) (Table 4). Children with a baseline BP above the 95th percentile of the same age and

sex and children who are allergic to this medicine should not use midodrine hydrochloride as treatment.

**Metoprolol** The initial dose is 0.5 mg/kg/day orally, twice daily, and can be gradually increased to a tolerable dose (no more than 2 mg/kg per day or the maximum adult daily dosage) [153] (IIa; A). Patients with significant sinus bradycardia, atrioventricular block (II or III degree), bronchial asthma, and allergy to drugs should be contraindicated to this therapy. Some biomarkers can predict the efficacy of metoprolol in such cases [115, 154–160] (IIa; B) (Table 4).

**Other drugs** Fludrocortisone may reduce the probability of VVS syncope events in children and adolescents [161] (IIa; B). There is limited experience regarding the application of sertraline in children and adolescents with VVS [162] (IIa; B), and it can be considered when other drugs are ineffective; however, side effects must be carefully monitored.

### Pacemaker therapy and others

Most children with VVS have a good prognosis [31] (I; C). For patients with recurrent syncope accompanied by prolonged cardiac arrest (>4 seconds) and those surviving cardiopulmonary resuscitation [10, 163, 164], pacemaker implantation can be considered under the recommendation of pediatric cardiovascular specialists [11], as it may reduce the incidence of syncope events [165]. Left atrial ganglion

catheter ablation can improve the symptoms of adults with VVS [166], and long-term follow-up of malignant VVS in children has achieved good results [167].

### Postural orthostatic tachycardia syndrome

The complicated pathophysiology and heterogeneous clinical manifestations of POTS pose a challenge to the treatment [168–172] (IIa; B) and require a comprehensive treatment plan [28]. The management of POTS in children and adolescents involves health education, pharmacological therapy, and other strategies [173–178]. Biomarker-oriented individualized therapy is an important strategy for the treatment of POTS [4, 124, 125, 179, 180] (IIa; B). However, it is also essential to focus on the management of the comorbidities [181] (IIa; B).

### Health education

**Avoidance of triggers** Patients should avoid prolonged standing, rapid changes in position from the supine or sitting or squatting to upright, taking drugs that aggravate symptoms, such as norepinephrine reuptake inhibitors, and being infected or fatigued [182] (IIa; B). Wearing compression garments can increase peripheral blood return and reduce orthostatic tachycardia caused by insufficient peripheral blood return [9] (I; C). At least 8 hours of sleep per day is also recommended [48, 173] (IIa; A). Patients with a salivary cortisol concentration  $> 4.1$  ng/mL upon waking up in the morning had better sleep-stimulating treatment effects [183] (IIa; B).

**Appropriate physical exercise** It is recommended to establish regular physical exercise plans for children and adolescents [184] (IIa; B) and ensure aerobic exercise for 1–2 hours/day for at least 5 days a week under parental supervision. Exercise can increase the blood volume of children, increase the left ventricular end-diastolic volume and stroke output, and enhance muscle pump function, thus improving the tolerance of children to upright positions. Some children with POTS have obvious exercise intolerance, and their exercise prescription should be gradual. Children who cannot tolerate long-term orthostatic exercise (such as long-distance running and ball sports) should start with non-orthostatic exercise. After 1–2 months of tolerating non-orthostatic exercise, they can gradually transition to orthostatic exercise and slowly prolong the time for exercise. A physical exercise plan should last for at least 3 months to form a lifestyle of exercise. However, other treatments should be considered for children with contraindications to sports [48] (IIa; A).

### Autonomic nervous function exercise

The protocols of autonomic nervous function exercise are the same as the corresponding part of the treatment of VVS. Children and adolescents suffering from POTS with QTd  $> 43$  ms are recommended to receive the autonomic nervous function exercise [185] (IIa; B).

### Increase salt and water intake

For managing POTS in children and adolescents, salt and water intake should be increased [186] (IIa; B). Some biomarkers can predict the fact that salt and water intake have better effects on POTS [187–190] (IIa; B) (Table 5). For children and adolescents with severe symptoms, intravenous saline infusion may relieve symptoms [9] (I; C).

### Pharmacological intervention

Pharmacological intervention should be considered for children and adolescents with severe symptoms that significantly affect the quality of life.

**Midodrine hydrochloride** The initial dose ranges from 1.25 to 2.5 mg/time orally, once or twice per day, and can be switched to 2.5 mg/time, three times per day after 2–4 weeks if the effect is not observed. Also, special attention should be paid to BP monitoring [191–197] (IIa; B). Some biomarkers can predict the effects of midodrine hydrochloride prior to treating POTS [191–200] (IIa; B) (Table 5). Generally, midodrine hydrochloride may be more effective than metoprolol or ORS in the treatment of children and adolescents with POTS [201] (IIa; B). The best curative effect can be achieved after 3 months of treatment, while extending the treatment course to 6 months does not significantly improve the therapeutic effect [202] (IIa; B). The contraindications are mentioned above (see section “Pharmacological intervention” of “Vasovagal syncope”).

**Metoprolol** The initial dose is 0.5 mg/kg/day orally, twice per day. This dosage can be gradually increased to a tolerable dose after 2–4 weeks but should be no more than 2mg/kg per day or the maximum adult daily dosage [1]. Some biomarkers can predict the effects of metoprolol [203–212] (IIa; B) (Table 5). A model with corrected maximum P-wave duration (ms), corrected minimum QT interval (ms), and Tped (ms) in ECG can predict the efficacy of metoprolol for children with POTS [209] (IIa; B). Metoprolol can reduce clinical symptom scores [201] (IIa; B). The contraindications are mentioned above (see section “Pharmacological intervention” of “Vasovagal syncope”).

**Table 5** Biomarkers for predicting therapeutic outcomes in children and adolescents with postural orthostatic tachycardia syndrome

Biomarkers and cutoff values	Clinical significance
MCHC > 347.5 g/L [179]	Increased intake of water and salt or oral rehydration salts may be recommended
24-h urinary sodium < 124 mmol [187]	Increased intake of water and salt or oral rehydration salts may be recommended
Body mass index < 18.02 kg/m <sup>2</sup> [188]	Increased intake of water and salt or oral rehydration salts may be recommended
Increase in HR (from the supine position to standing) > 41 bpm [189]	Increased intake of water and salt or oral rehydration salts may be recommended
The maximum HR during active standing test > 123 bpm [189]	Increased intake of water and salt or oral rehydration salts may be recommended
Baroreflex sensitivity > 17.01 ms/mmHg [190]	Increased intake of water and salt or oral rehydration salts may be recommended
Plasma copeptin level > 10.5 pmol/L [192]	Midodrine hydrochloride may be recommended
Increase in SBP (from the supine position to upright) ≤ 0 mmHg [193]	Midodrine hydrochloride may be recommended
Increase in DBP (from the supine position to upright) ≤ 6.5 mmHg [193]	Midodrine hydrochloride may be recommended
Flow-mediated vasodilation > 9.85% [196]	Midodrine hydrochloride may be recommended
Erythrocyte hydrogen sulfide production > 27.1 nmol/min/10 <sup>8</sup> RBC [197]	Midodrine hydrochloride may be recommended
Plasma MR-proADM level > 61.5 pg/mL [199]	Midodrine hydrochloride may be recommended
Poincaré plot longitudinal axis < 573.9 ms and transverse/longitudinal axis ratio > 2.9 [200]	Midodrine hydrochloride may be recommended
Plasma copeptin level < 10.2 pmol/L [203]	Metoprolol may be recommended
Plasma C-type natriuretic peptide > 32.55 pg/mL [204]	Metoprolol may be recommended
Orthostatic plasma norepinephrine level > 3.59 pg/mL [205]	Metoprolol may be recommended
Baroreflex sensitivity > 8.045 ms/mmHg [206]	Metoprolol may be recommended
HR variability TR ≤ 33.7 and SDNN index ≤ 79.0 ms [207]	Metoprolol may be recommended
Baseline QT interval dispersion > 37 ms [208]	Metoprolol may be recommended
Corrected QT interval dispersion > 47.9 ms [208]	Metoprolol may be recommended
Corrected maximum P-wave duration > 109 ms, corrected minimum QT interval > 382.5 ms, and T-wave apex to T-wave end interval dispersion > 45.6 ms [209]	Metoprolol may be recommended
5-min HR at HUTT > 110 bpm [210]	Metoprolol may be recommended
10-min HR at HUTT > 112 bpm [210]	Metoprolol may be recommended
5-min HR difference from baseline HR at HUTT > 34 bpm [210]	Metoprolol may be recommended
10-min HR difference from baseline HR at HUTT > 37 bpm [210]	Metoprolol may be recommended
The product of HR and BP at 5-min during HUTT > 11,548.5 bpm × mmHg [211]	Metoprolol may be recommended
The product of HR and BP at 10-min during HUTT > 10,988.0 bpm × mmHg [211]	Metoprolol may be recommended

MCHC mean erythrocyte hemoglobin concentration, HR heart rate, BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, RBC red blood cell, MR-proADM mid-regional fragment of pro-adrenomedullin, TR triangulation index, SDNN standard deviation of all NN intervals, HUTT head-up tilt test

### Management of comorbidities

Correcting iron and vitamin deficiencies may be beneficial in improving the symptoms of patients with POTS [213–215] (IIa; B). The evaluation and management of POTS comorbidities are also receiving increasing attention [182, 216]. Other common comorbidities of POTS include allergic diseases, migraines, mental disorders, sleeping disorders, hyperventilation syndrome, chronic fatigue syndrome, joint

hypermobility syndrome, and gastrointestinal disorders. The treatment of POTS in children requires a comprehensive assessment of the comorbidities [184] (IIa; B).

### Orthostatic hypotension

OH can be managed firstly using non-pharmacological measures, such as avoiding triggers, increasing water and salt intake, taking physical counter-pressure maneuvers, and

wearing elastic socks [217–219] (IIa; B). If non-pharmacological treatments are not effective, midodrine hydrochloride or fludrocortisone can be considered [2] (I; C).

### Orthostatic hypertension

Non-pharmacological therapy [220], including health education and autonomic function exercise, can be used. Health education includes knowledge on avoiding prolonged standing or sudden changes in position (from supine or sitting or squatting to an upright position) and providing psychological assistance. Currently, no medicines have been recommended for the treatment of OHT in children. However, special attention should be paid to the possibility of developing primary hypertension during late adolescence or adulthood in children with OHT.

### Other types of neurally mediated syncope

Children and adolescents with SS usually experience recurrent syncope under specific circumstances [57, 58] (IIa; B). For example, the treatment of micturition syncope is health education. It is suggested that the patient should not stand up abruptly when getting up in the morning and avoid holding urine for a long period. It is recommended to micturate in a squatting position. If a syncopal attack occurs during micturition, the witness should assist the patient to lay down in a safe and well-ventilated environment and retain a unobstructed airway for the patient. For children with breath-holding spells, only health education and an explanation of the prognosis of the disease are needed, which means that the parents should understand that the attacks are generally not life-threatening. During a breath-holding spell, the parents need to ensure that their child lies on his or her side to prevent trauma and aspiration.

### Follow-up

The prognosis of most children and adolescents with VVS or POTS is generally good, but regular follow-up is still needed to get better outcomes [221–223] (IIa; B). A follow-up at 1–3 months after the initial diagnosis and treatment is recommended, and the interval for follow-up thereafter should depend on the symptoms of the patients. Children and adolescents with more than four episodes of syncope have a reduced symptom-free rate [224] (IIa; B), while those with cardiac arrest or convulsive events during HUTT do not indicate a poor prognosis [81] (IIa; B).

In the follow-up of VVS, the frequency and manifestations of symptoms, treatment compliance, and drug tolerance should be recorded. The recurrent onset of symptoms is the main factor affecting the quality of life of children and adolescents [132] (IIa; B). Supine mean arterial pressure in

HUTT, baseline urine specific gravity, the standard deviation of average RR intervals in milliseconds, mean corpuscular hemoglobin, and demographic factors are associated with the risk of syncope or presyncope recurrence [80, 225, 226] (IIa; B). The evaluation of therapeutic efficacy should mainly focus on symptom control [205] (IIa; B). A symptom score, which is based on the frequency of syncopal episodes, has been used to evaluate the efficacy [143] (IIa; B). A negative response to HUTT is not recommended as an effective indicator for treatment.

In the follow-up of children with POTS, the OI symptom score is recommended as an indicator to judge the therapeutic effect, and a score reduction of  $\geq 2$  points is considered effective [192] (IIa; B). If the treatment effect is not good, the condition of the patient should be re-evaluated to ensure that the diagnosis is correct and the treatment plan adjusted [227] (IIa; B). In addition, the influence of comorbidity should be considered. The duration of symptoms before treatment and the maximum upright HR in a standing position can be used as independent indicators to estimate the long-term prognosis, with patients receiving conventional intervention for POTS generally experiencing satisfactory long-term outcomes [228] (IIa; B). A baseline plasma mid-regional fragment of pro-adrenomedullin  $> 61.5$  ng/L indicates that midodrine hydrochloride has a favorable long-term effect [229] (IIa; B). In a questionnaire survey, a total of 86% of children and adolescents with POTS showed symptomatic remission 5 years after their initial diagnosis [230] (IIa; B).

### Conclusions

In summary, based on the latest global research reports, the guidelines were updated. In terms of the diagnosis of NMS as well as its related disorders in children, the concepts of STS and SHT were introduced; and the comorbidities of NMS were emphasized. Regarding the management, the detailed rules and recommendations for some non-pharmacological therapies were refined and the management of comorbidities was highlighted. Specially, the newly discovered biomarkers that can be used to guide individualized treatment in recent years were summarized and recommended. Furthermore, specific suggestions were put forward for the follow-up process and efficacy evaluation. The new guidelines will provide comprehensive guidance and reference for the diagnosis and treatment of NMS in children and adolescents. It is expected that the guidelines will be further improved and perfected in the future clinical practice and related studies.

**Acknowledgements** We acknowledged Chinese Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association; Committee of Pediatric Syncope, College of Pediatricians, Chinese Medical Doctor Association; Pediatric Cardiology Society, Beijing Pediatric

Society, Beijing Medical Association; Committee of Pediatric Cardiology, College of Cardiovascular Physicians, Chinese Medical Doctor Association. The panelists: Jin-Dou An, Xin-Jiang An, Jie Chen, Li-Qing Chen, Ming-Wu Chen, Shu-Qin Chen, Qi Chen, Yong-Hong Chen, Sun Chen, Zhi Chen, Adolphus Kai-tung Chau, Mao-Ping Chu, Hui-Ying Cui, Xiang-Yu Dong, Jun-Bao Du, Shu-Xu Du, Zhong-Dong Du, Hong-Yu Duan, Jun-Kai Duan, Lin Feng, Li-Jun Fu, Fang Gao, Lu Gao, Wei Gao, Fang-Qi Gong, Li Gu, Hong Gu, Yong-Hao Gui, Zhen-Hui Han, Bo Han, Ling Han, Bing He, Xue-Hua He, Zhi-Xu He, Xiu-Fen Hu, Yao-Fei Hu, Yi-Min Hua, Guo-Ying Huang, Hui-Tao Huang, Min Huang, Ping Huang, Xing-Yuan Huang, Yu-Juan Huang, Shou-Yuan Jiang, Hong-Fang Jin, Mei Jin, Yan-Zhe Lei, Bo Li, Fen Li, Li Li, Tao Li, Xiao-Ming Li, Xiao-Hui Li, Yan Li, Yun Li, Zi-Pu Li, Yong-Mei Liang, Ying Liao, Fang Liu, Wei Liu, Xiao-Yan Liu, Ya-Li Liu, Hui-Ling Lu, Hai-Tao Lv, Tie-Wei Lv, Lu-Yi Ma, Bao-Quan Pan, Xiang-Bin Pan, Si-Lin Pan, Yu-Sheng Pang, Hua Peng, Jin-Hua Piao, Ming-Yang Qian, Wei Qian, Yu-Ming Qin, Jie Shen, Lin Shi, Guo-Dong Song, Jing-Hui Sun, Kun Sun, Li-An Sun, Ling Sun, Yan Sun, Hong Tian, Jie Tian, Cheng Wang, Cui-Ling Wang, Hong Wang, Lei Wang, Li-Hong Wang, Lin Wang, Qin Wang, Shu-Shui Wang, Wen-Di Wang, Xiao-Ning Wang, Yi-Biao Wang, Jian-Xin Wu, Rong-Zhou Wu, Yu-Rong Wu, Kun Xia, Ting-Ting Xiao, Yan-Yan Xiao, Li-Jian Xie, Yu-Mei Xie, Chun-Hong Xie, Yan-Lin Xing, Zhen-Yu Xiong, Bao-Yuan Xu, Yi Xu, Hui Yan, Jian-Ping Yang, Shi-Wei Yang, Qi-Jian Yi, Xia Yu, Xian-Yi Yu, Yue Yuan, Du-Fei Zhang, Hong-Yan Zhang, Hui-Li Zhang, Kun Zhang, Li Zhang, Ming-Ming Zhang, Qing-You Zhang, Xi Zhang, Yan-Min Zhang, Yong Zhang, Zhi-Wei Zhang, Cui-Fen Zhao, Bin Zhou, Kai-Yu Zhou, Hua Zhu, Sheng-Dong Zhu, Jian-Xin Zhuang.

**Author contributions** WC, LY and WS contributed equally to this work. WC drafted and revised the manuscript, and carried out the evidence-based methodology. LY carried out the evidence-based methodology and revised the final manuscript. WS drafted and revised the manuscript. TH, HM, DXY, SL, LYQ, and SJH revised and suggested changes to the manuscript. DJB and JHF designed the manuscript and revised the final manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

**Funding** This manuscript was supported by the National High-Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital; 2022CR59).

**Data availability** The data are available from the corresponding author on reasonable request.

## Declarations

**Ethical approval** Not required.

**Conflict of interest** No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. Author Jun-Bao Du is a member of the Editorial Board for *World Journal of Pediatrics*. The paper was handled by the other editor and has undergone a rigorous peer review process. Author Jun-Bao Du was not involved in the journal's review or decisions related to this manuscript. The authors have no conflict of interest to declare.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Wang C, Li Y, Liao Y, Tian H, Huang M, Dong X, et al. 2018 Chinese Pediatric Cardiology Society (CPCS) guideline for diagnosis and treatment of syncope in children and adolescents. *Sci Bull (Beijing)*. 2018;63:1558–64.
2. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC guidelines for the diagnosis and management of syncope. *Eur Heart J*. 2018;39:1883–948.
3. Kenny RA, Brignole M, Dan GA, Deharo JC, van Dijk JG, Doherty C, et al. Syncope unit: rationale and requirement—the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society. *Europace*. 2015;17:1325–40.
4. Tao C, Tang C, Jin H, Du J. Pediatric syncope: a hot issue in focus. *Sci Bull (Beijing)*. 2020;65:513–5.
5. Hu E, Liu X, Chen Q, Wang C. Investigation on the incidence of syncope in children and adolescents aged 2–18 years in Changsha. *Front Pediatr*. 2021;9:638394.
6. Ruwald MH, Hansen ML, Lamberts M, Hansen CM, Højgaard MV, Køber L, et al. The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study. *Europace*. 2012;14:1506–14.
7. Chen L, Li X, Todd O, Wang C, Jin H, Du J. A clinical manifestation-based prediction of haemodynamic patterns of orthostatic intolerance in children: a multi-centre study. *Cardiol Young*. 2014;24:649–53.
8. Kara A, Doğan MT. The psychopathology, depression, and anxiety levels of children and adolescents with vasovagal syncope: a case-control study. *J Nerv Ment Dis*. 2021;209:547–51.
9. Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. *Heart Rhythm*. 2015;12:e41–63.
10. Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American college of cardiology/American heart association task force on clinical practice guidelines, and the heart rhythm society. *J Am Coll Cardiol*. 2017;70:e39–110.
11. Sanatani S, Chau V, Fournier A, Dixon A, Blondin R, Sheldon RS. Canadian Cardiovascular Society and Canadian Pediatric Cardiology Association Position Statement on the approach to syncope in the pediatric patient. *Can J Cardiol*. 2017;33:189–98.
12. Wang Y, Wang Y, He B, Tao C, Han Z, Liu P, et al. Plasma human growth cytokines in children with vasovagal syncope. *Front Cardiovasc Med*. 2022;9:1030618.
13. Zhang Q, Sun Y, Zhang C, Qi J, Du J. Vitamin D deficiency and vasovagal syncope in children and adolescents. *Front Pediatr*. 2021;9:575923.
14. Zhang Q, Li Y, Liao Y, Du J. Significance of red cell distribution width in the differential diagnosis between neurally mediated syncope and arrhythmic syncope in children. *Cardiol Young*. 2017;27:691–6.
15. Bai W, Chen S, Tang CS, Qi JG, Cui QH, Xu M, et al. Gut microbiota analysis and its significance in vasovagal syncope in children. *Chin Med J (Engl)*. 2019;132:411–9.

16. Chen L, Zhang CY, Du JB. Diagnostic values of heart rate variability on unexplained syncope in children. *Beijing Da Xue Xue Bao Yi Xue Ban*. 2013;45:761–5 (in Chinese).
17. Cui YX, Du JB, Jin HF. Insights into postural orthostatic tachycardia syndrome after COVID-19 in pediatric patients. *World J Pediatr*. 2024;20:201–7.
18. Jin HF, Yang JY, Li XY, Zhu LL, Han L, Zhang FW, et al. A modified Calgary syncope syndrome score in the differential diagnosis between cardiac syncope and vasovagal syncope. *Zhonghua Er Ke Za Zhi*. 2012;50:117–20 (in Chinese).
19. Yang J, Zhu L, Chen S, Li X, Zhang Q, Zhang F, et al. Modified Calgary score in differential diagnosis between cardiac syncope and postural orthostatic tachycardia syndrome-associated syncope in children. *Cardiol Young*. 2013;23:400–4.
20. Zou R, Wang S, Zhu L, Wu L, Lin P, Li F, et al. Calgary score and modified Calgary score in the differential diagnosis between neurally mediated syncope and epilepsy in children. *Neurol Sci*. 2017;38:143–9.
21. Li Y, Liu J, Wang M, Zhao H, Liu X, Hu J, et al. Predictive value of EGSYS score in the differential diagnosis of cardiac syncope and neurally mediated syncope in children. *Front Cardiovasc Med*. 2023;10:1091778.
22. Zhang J, Tang HN, Wang YW, Li F, Cai H, Lin P, et al. Predictive value of blood cell parameters in the diagnosis of vasovagal syncope in children. *Zhonghua Er Ke Za Zhi*. 2022;60:792–7 (in Chinese).
23. Zhao J, Du JB. Blood pressure variability in children with autonomous nerve mediated syncope. *Zhonghua Er Ke Za Zhi*. 2012;50:712–3 (in Chinese).
24. Zou R, Wang S, Cai H, Li F, Lin P, Wang Y, et al. Vitamin D deficiency in children with vasovagal syncope is associated with impaired circadian rhythm of blood pressure. *Front Neurosci*. 2021;15:712462.
25. Li J, Zhang Q, Gao J, Jin H, Du J. Significance of serum iron in the differential diagnosis between vasovagal syncope and postural orthostatic tachycardia syndrome in children. *Beijing Da Xue Xue Bao Yi Xue Ban*. 2013;45:923–7 (in Chinese).
26. Jin HF, Du JB. Development and future direction of clinical diagnosis and management of pediatric syncope. *Zhonghua Er Ke Za Zhi*. 2020;58:88–90 (in Chinese).
27. Chen L, Wang C, Wang H, Tian H, Tang C, Jin H, et al. Underlying diseases in syncope of children in China. *Med Sci Monit*. 2011;17:PH49–53.
28. Cui Y, Liao Y, Zhang Q, Yan H, Liu P, Wang Y, et al. Spectrum of underlying diseases in syncope and treatment of neurally-mediated syncope in children and adolescents over the past 30 years: a single center study. *Front Cardiovasc Med*. 2022;9:1017505.
29. Li HX, Gao L, Yuan Y. Advance in the understanding of vasovagal syncope in children and adolescents. *World J Pediatr*. 2021;17:58–62.
30. Zhang QY, Karmane SI, Du JB. Physiologic neurocirculatory patterns in the head-up tilt test in children with orthostatic intolerance. *Pediatr Int*. 2008;50:195–8.
31. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J*. 2009;30:2631–71.
32. Zhang W, Wang C, Zou R, Liu L, Wu L, Luo X, et al. Changes in P-wave, T-wave, and ST segment amplitude in 12 lead electrocardiogram in children with breath holding spell. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2016;41:600–5 (in Chinese).
33. Wang YR, Li XY, Du JB, Sun Y, Xu WR, Wang YL, et al. Impact of comorbidities on the prognosis of pediatric vasovagal syncope. *World J Pediatr*. 2022;18:624–8.
34. Liao Y, Zhang QY, Li HX, Wang YL, Liu P, Du JB. Comorbidity of vasovagal syncope and postural tachycardia syndrome with allergic diseases in children. *Beijing Da Xue Xue Bao Yi Xue Ban*. 2017;49:783–8 (in Chinese).
35. Wang Y, Du J, Jin H, Liao Y. Comorbidity of neurally mediated syncope and allergic disease in children. *Front Immunol*. 2020;11:1865.
36. Quan W, Wang Y, Chen S, Du J. Orthostatic intolerance and coagulation abnormalities: an update. *Neurosci Bull*. 2019;35:171–7.
37. Zou R, Wang S, Liu P, Chen D, Yan J, Cai H, et al. The association between patent foramen ovale and unexplained syncope in pediatric patients. *Ital J Pediatr*. 2024;50:2.
38. Liao Y, Qi JG, Yan H, Zhang QY, Ji TY, Chang XZ, et al. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (*MTHFR*) mutation in an adolescent: a case report. *Chin Med J (Engl)*. 2021;134:1495–7.
39. Gao Y, Zhang Q, Sun Y, Du J. Congenital anomalous origin of coronary artery disease in children with syncope: a case series. *Front Pediatr*. 2022;10:879753.
40. Chen L, Zhang Q, Ingrid S, Chen J, Qin J, Du J. Aetiologic and clinical characteristics of syncope in Chinese children. *Acta Paediatr*. 2007;96:1505–10.
41. Liao Y, Du J, Benditt DG, Jin H. Vasovagal syncope or psychogenic pseudosyncope: a major issue in the differential diagnosis of apparent transient loss of consciousness in children. *Sci Bull (Beijing)*. 2022;67:1618–20.
42. Zhang Z, Jiang X, Han L, Chen S, Tao L, Tao C, et al. Differential diagnostic models between vasovagal syncope and psychogenic pseudosyncope in children. *Front Neurol*. 2020;10:1392.
43. Li C, Zhang Y, Liao Y, Han L, Zhang Q, Fu J, et al. Differential diagnosis between psychogenic pseudosyncope and vasovagal syncope in children: a quantitative scoring model based on clinical manifestations. *Front Cardiovasc Med*. 2022;9:839183.
44. Li YW, Chen L, Du JB, Yang YY, Jin HF. Cost-effectiveness of diagnostic approaches to vasovagal syncope. *Chin Med J (Engl)*. 2010;123:2635–9.
45. Chen L, Yang YY, Wang C, Wang HW, Tian H, Zhang QY, et al. A multi-center study of hemodynamic characteristics exhibited by children with unexplained syncope. *Chin Med J (Engl)*. 2006;119:2062–8.
46. Tretter JT, Kavey RE. Distinguishing cardiac syncope from vasovagal syncope in a referral population. *J Pediatr*. 2013;163:1618–23.
47. Tao C, Han Z, Yan Y, Pan Z, Zhu H, Li X, et al. Sitting-induced hemodynamic changes and association with sitting intolerance in children and adolescents: a cross-sectional study. *Sci Rep*. 2020;10:13921.
48. Wang Y, Han Z, Wang Y, Yan Y, Pan Z, Zhu H, et al. Risk factors of sitting-induced tachycardia syndrome in children and adolescents. *PLoS One*. 2022;17:e0265364.
49. Wang YY, Du JB, Jin HF. Differential diagnosis of vasovagal syncope and postural tachycardia syndrome in children. *World J Pediatr*. 2020;16:549–52.
50. Zhang Q, Jin H, Qi J, Yan H, Du J. Diagnostic value of serum brain natriuretic peptide in syncope in children and adolescents. *Acta Paediatr*. 2013;102:e210–4.
51. Wang X, Wang S, Xiao H, Zou R, Cai H, Liu L, et al. The value of QT interval in differentiating vasovagal syncope from epilepsy in children. *Ital J Pediatr*. 2022;48:197.
52. Lin J, Zhao H, Ma L, Jiao F. Body mass index is decreased in children and adolescents with postural tachycardia syndrome. *Turk J Pediatr*. 2019;61:52–8.
53. Wang Y, Zhang C, Chen S, Li X, Jin H, Du J. Frequency domain indices of heart rate variability are useful for differentiating vasovagal syncope and postural tachycardia syndrome in children. *J Pediatr*. 2019;207:59–63.

54. Tao C, Chen S, Li H, Wang Y, Wang Y, Liu P, et al. Value of immediate heart rate alteration from supine to upright in differential diagnosis between vasovagal syncope and postural tachycardia syndrome in children. *Front Pediatr*. 2018;6:343.
55. Zhang F, Li X, Stella C, Chen L, Liao Y, Tang C, et al. Plasma hydrogen sulfide in differential diagnosis between vasovagal syncope and postural orthostatic tachycardia syndrome in children. *J Pediatr*. 2012;160:227–31.
56. Yuan P, Lian Z, Wang Y, Wang Y, Zhang C, Du J, et al. Poincaré plot is useful for distinguishing vasovagal syncope from postural tachycardia syndrome in children. *Front Pediatr*. 2022;10:758100.
57. Zou R, Wang S, Lin P, Hu C, Wang Y, Li F, et al. The clinical characteristics of situational syncope in children and adults undergoing head-up tilt testing. *Am J Emerg Med*. 2020;38:1419–23.
58. Trivedi MK, Arora G. Micturition syncope with asystole in a paediatric patient. *Cardiol Young*. 2021;31:661–2.
59. Choi YJ, Kang KW, Jang SH, Kim JG, Lee SJ, Jung KT. Heart rate recovery and diastolic blood pressure ratio on the treadmill test predict an induction and recurrence of vasovagal syncope. *Korean J Intern Med*. 2019;34:315–23.
60. Zhang Q, Zhu L, Wang C, Du Z, Hu X, Tian H, et al. Value of history taking in children and adolescents with cardiac syncope. *Cardiol Young*. 2013;23:54–60.
61. Stewart JM. Common syndromes of orthostatic intolerance. *Pediatrics*. 2013;131:968–80.
62. Placidi S, Drago F, Milioni M, Verticelli L, Tamburri I, Silvetti MS, et al. Miniaturized implantable loop recorder in small patients: an effective approach to the evaluation of subjects at risk of sudden death. *Pacing Clin Electrophysiol*. 2016;39:669–74.
63. Huang YJ, Zhou ZW, Xu M, Ma QW, Yan JB, Wang JY, et al. Alteration of gene expression profiling including *GPR174* and *GNG2* is associated with vasovagal syncope. *Pediatr Cardiol*. 2015;36:475–80.
64. Zhang QY, Du JB, Chen JJ, Li WZ. Association of clinical characteristics of unexplained syncope with the outcome of head-up tilt tests in children. *Pediatr Cardiol*. 2004;25:360–4.
65. Li H, Han Z, Chen S, Liao Y, Wang Y, Liu P, et al. Total peripheral vascular resistance, cardiac output, and plasma C-type natriuretic peptide level in children with postural tachycardia syndrome. *J Pediatr*. 2015;166:1385–9.e1–2.
66. Zhao J, Han Z, Zhang X, Du S, Liu AD, Holmberg L, et al. A cross-sectional study on upright heart rate and BP changing characteristics: basic data for establishing diagnosis of postural orthostatic tachycardia syndrome and orthostatic hypertension. *BMJ Open*. 2015;5:e007356.
67. Cai H, Wang S, Zou R, Li F, Zhang J, Wang Y, et al. Diagnostic value of diurnal variability of orthostatic heart rate increment in children and adolescents with POTS. *Front Pediatr*. 2021;9:644461.
68. Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. *J Am Coll Cardiol*. 2015;66:848–60.
69. Zhang Q, Li J, Xie Y, Zhao J, Du J. Orthostatic hypertension in children and adolescents with postural tachycardia syndrome. *J Trap Pediatr*. 2014;60:461–6.
70. Wang Y, Xu Y, Li F, Lin P, Zhang J, Zou R, et al. Diagnostic and prognostic value of T-wave amplitude difference between supine and orthostatic electrocardiogram in children and adolescents with postural orthostatic tachycardia syndrome. *Ann Noninvasive Electrocardiol*. 2020;25:e12747.
71. Tan C, Yi X, Chen Y, Wang S, Ji Q, Li F, et al. The changes of T-wave amplitude and QT interval between the supine and orthostatic electrocardiogram in children with dilated cardiomyopathy. *Front Pediatr*. 2021;9:680923.
72. Macedo PG, Leite LR, Santos-Neto L, Hachul D. Tilt test—from the necessary to the indispensable. *Arq Bras Cardiol*. 2011;96:246–54 (in English, Portuguese, Spanish).
73. Robinson JA, Shivapour JK, Snyder CS. Tilt table testing to diagnose pseudosyncope in the pediatric population. *Congenit Heart Dis*. 2017;12:411–6.
74. Lin J, Wang Y, Ochs T, Tang C, Du J, Jin H. Tilt angles and positive response of head-up tilt test in children with orthostatic intolerance. *Cardiol Young*. 2015;25:76–80.
75. Thijs RD, Brignole M, Falup-Pecurariu C, Fanciulli A, Freeman R, Guaraldi P, et al. Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness: consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). *Clin Auton Res*. 2021;31:369–84.
76. Zou R, Wang S, Li F, Lin P, Zhang J, Wang Y, et al. The application of head-up tilt test to diagnose hemodynamic type of orthostatic intolerance in children aged between 3 to 5 years old. *Front Pediatr*. 2021;9:623880.
77. Li W, Wang C, Wu LJ, Hu CY, Xu Y, Li MX, et al. Arrhythmia after a positive head-up tilt table test. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2010;38:805–8 (in Chinese).
78. Chu W, Wang C, Lin P, Li F, Wu L, Xie Z. Transient aphasia: a rare complication of head-up tilt test. *Neurol Sci*. 2014;35:1127–32.
79. Wang C, Li W, Wu L, Lin P, Li F, Luo H, et al. Clinical characteristics and treatment of 89 patients with head-up tilt table test induced syncope with convulsion. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2013;38:70–3 (in Chinese).
80. Wang S, Peng Y, Zou R, Wang Y, Cai H, Li F, et al. The relationship between demographic factors and syncopal symptom in pediatric vasovagal syncope. *Sci Rep*. 2023;13:22724.
81. Zou R, Wang S, Wen W, Cai H, Wang Y, Liu P, et al. Risk factors and prognostic follow-up of vasovagal syncope children with seizure-like activities during head-up tilt test induced-syncope. *Front Cardiovasc Med*. 2022;9:916542.
82. Liao D, Xu Y, Zou R, Wu L, Luo X, Li F, et al. The circadian rhythm of syncopal episodes in patients with neurally mediated syncope. *Int J Cardiol*. 2016;215:186–92.
83. Li H, Liao Y, Han Z, Wang Y, Liu P, Zhang C, et al. Head-up tilt test provokes dynamic alterations in total peripheral resistance and cardiac output in children with vasovagal syncope. *Acta Paediatr*. 2018;107:1786–91.
84. Liao Y, Chen S, Liu X, Zhang Q, Ai Y, Wang Y, et al. Flow-mediated vasodilation and endothelium function in children with postural orthostatic tachycardia syndrome. *Am J Cardiol*. 2010;106:378–82.
85. Zhang QY, Du JB, Li WZ. Head-up tilt testing potentiated with sublingual nitroglycerin for the diagnosis of unexplained syncope in children. *Zhonghua Er Ke Za Zhi*. 2004;42:371–4 (in Chinese).
86. Zhang W, Zou R, Wu L, Luo X, Xu Y, Li F, et al. The changes of electrolytes in serum and urine in children with neurally mediated syncope cured by oral rehydration salts. *Int J Cardiol*. 2017;233:125–9.
87. Zhang Q, Du J, Wang C, Du Z, Wang L, Tang C. The diagnostic protocol in children and adolescents with syncope: a multi-centre prospective study. *Acta Paediatr*. 2009;98:879–84.
88. Liao Y, Xu WR, Li HX, Tang CS, Jin HF, Du JB. Plasma neuropeptide Y levels in vasovagal syncope in children. *Chin Med J (Engl)*. 2017;130:2778–84.
89. Wang S, Peng Y, Zou R, Liao D, Yan J, Chen D, et al. Relationship between hemodynamic type and syncopal symptoms in pediatric vasovagal syncope. *Eur J Pediatr*. 2024;183:179–84.

90. Xu WR, Jin HF, Du JB. Diagnosis and treatment of malignant vasovagal syncope in children. *Zhonghua Er Ke Za Zhi*. 2022;60:64–6 (in Chinese).
91. Sun R, Kang YY, Zhang MM, Li AJ, Lin Y, Shi L, et al. Risk factors associated with malignant vasovagal syncope in children. *Zhonghua Er Ke Za Zhi*. 2023;61:131–5 (in Chinese).
92. Brewster JA, Garland EM, Biaggioni I, Black BK, Ling JF, Shibao CA, et al. Diurnal variability in orthostatic tachycardia: implications for the postural tachycardia syndrome. *Clin Sci (Lond)*. 2012;122:25–31.
93. Moon J, Lee HS, Byun JI, Sunwoo JS, Shin JW, Lim JA, et al. The complexity of diagnosing postural orthostatic tachycardia syndrome: influence of the diurnal variability. *J Am Soc Hypertens*. 2016;10:263–70.
94. Hu Y, Wang Y, He B, Wang Y, Han Z, Tao C, et al. Sympathetic overactivation from supine to upright is associated with orthostatic hypertension in children and adolescents. *Front Pediatr*. 2020;8:54.
95. Zhao J, Yang J, Du S, Tang C, Du J, Jin H. Changes of atrial natriuretic peptide and antidiuretic hormone in children with postural tachycardia syndrome and orthostatic hypertension: a case control study. *Chin Med J (Engl)*. 2014;127:1853–7.
96. Lee H, Low PA, Kim HA. Patients with orthostatic intolerance: relationship to autonomic function tests results and reproducibility of symptoms on tilt. *Sci Rep*. 2017;7:5706.
97. Markiewicz-Łoskot G, Kolarczyk E, Mazurek B, Łoskot M, Szydłowski L. Prolongation of electrocardiographic T wave parameters recorded during the head-up tilt table test as independent markers of syncope severity in children. *Int J Environ Res Public Health*. 2020;17:6441.
98. Chu WH, Wu LJ, Wang C, Lin P, Li F, Zhu LP, et al. Evaluation of psychological fear in children undergoing head-up tilt test. *Zhongguo Dang Dai Er Ke Za Zhi*. 2014;16:263–7 (in Chinese).
99. Lai WT, Chen MR, Lin SM, Hwang H. Application of head-up tilt table testing in children. *J Formos Med Assoc*. 2010;109:641–6.
100. Wang S, Peng Y, Wang Y, Li F, Xu Y, Zheng H, et al. Relationship between syncope symptoms and HUTT modes. *Cardiol Young*. 2024. <https://doi.org/10.1017/S1047951124000726>.
101. Cui YX, Du JB, Zhang QY, Liao Y, Liu P, Wang YL, et al. A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children. *Beijing Da Xue Xue Bao Yi Xue Ban*. 2022;54:954–60 (in Chinese).
102. Gao Y, Jin H, Du J. Sitting intolerance: a new disease entity in children and adolescents. *Pediatr Investig*. 2022;6:299–301.
103. Cai H, Wang S, Zou R, Liu P, Li F, Wang Y, et al. Comparison of the active sitting test and head-up tilt test for diagnosis of postural tachycardia syndrome in children and adolescents. *Front Pediatr*. 2021;9:691390.
104. Boris JR, Huang J, Shuey T, Bernadzikowski T, Boris JR, Huang J, et al. Family history of associated disorders in patients with postural tachycardia syndrome. *Cardiol Young*. 2020;30:388–94.
105. Landwehr K, Meyer S, Flotats-Bastardas M, Poryo M. Syncope in children and adolescents are the current guidelines being followed? *Wien Med Wochenschr*. 2021;171:157–64 (in German).
106. Blanc JJ. Clinical laboratory testing: what is the role of tilt-table testing, active standing test, carotid massage, electrophysiological testing and ATP test in the syncope evaluation? *Prog Cardiovasc Dis*. 2013;55:418–24.
107. Stewart JM, van Dijk JG, Balaji S, Sutton R. A framework to simplify paediatric syncope diagnosis. *Eur J Pediatr*. 2023;182:4771–80.
108. Wang C, Mao D, Li M, Lin P, Li W, Zheng H. Diagnostic difference of head-up tilt table test in the patients of unexplained dizziness and syncope. *Chin J Crit Care Med*. 2005;25:796–9 (in Chinese).
109. Wang Y, Wang S, Zou R, Chen S, Li F, Wang Y, et al. The relationship between unexplained chest pain in children and head-up tilt test. *Front Pediatr*. 2022;10:901919.
110. Zou R, Wang S, Li F, Lin P, Zhang J, Wang Y, et al. Clinical characteristics and hemodynamic responses to head-up tilt test in children and adolescents with unexplained sighing. *Neuro Sci*. 2021;42:3343–7.
111. Gan T, Wu L, Zou R, Lin P, Li F, Yang H, et al. Relationship between unexplained palpitation in children and head-up tilt test. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2018;43:282–6 (in Chinese).
112. Yan H, Zhang C, Du J, Jin H. Clinical significance of abdominal pain and other gastrointestinal manifestations in children with autonomic nervous-mediated syncope. *Chin J Pract Pediatr*. 2013;28:43–7 (in Chinese).
113. Zhang LN, Moak JP, Desbiens J, Hanumanthaiah S, Fabian RR, Clarke L, et al. Utility of diagnostic studies for upper gastrointestinal symptoms in children with orthostatic intolerance. *J Pediatr*. 2019;205:138–44.
114. Yang J, Li H, Ochs T, Zhao J, Zhang Q, Du S, et al. Erythrocytic hydrogen sulfide production is increased in children with vasovagal syncope. *J Pediatr*. 2015;166:965–9.
115. Zhang QY, Du JB, Zhen JL, Li WZ, Wang YL. Hemodynamic changes during head-up tilt test and predictive value thereof in predicting the efficacy of metoprolol therapy in children with vasovagal syncope. *Zhonghua Yi Xue Za Zhi*. 2007;87:1260–2 (in Chinese).
116. Lin J, Han Z, Li X, Ochs T, Zhao J, Zhang X, et al. Risk factors for postural tachycardia syndrome in children and adolescents. *PLoS One*. 2014;9:e113625.
117. Zhang Q, Chen X, Li J, Du J. Clinical features of hyperadrenergic postural tachycardia syndrome in children. *Pediatr Int*. 2014;56:813–6.
118. Hu Y, He B, Han Z, Wang Y, Tao C, Wang Y, et al. Risk factors for orthostatic hypertension in children. *J Pediatr*. 2020;227:212–7.e1.
119. Zhao J, Yang JY, Jin HF, Du JB. Clinical analysis of orthostatic hypertension in children. *Zhonghua Er Ke Za Zhi*. 2012;50:839–42 (in Chinese).
120. Tao C, Cui Y, Zhang C, Liu X, Zhang Q, Liu P, et al. Clinical efficacy of empirical therapy in children with vasovagal syncope. *Children (Basel)*. 2022;9:1065.
121. Xiao YY, Jin M, Ye WQ, Han L, Jin HF. Individualized treatment of syncope in children: state-of-the-art. *Chin Med J (Engl)*. 2017;130:2878–80.
122. Xu WR, Du JB, Jin HF. Can pediatric vasovagal syncope be individually managed? *World J Pediatr*. 2022;18:4–6.
123. Zhao T, Wang S, Wang M, Cai H, Wang Y, Xu Y, et al. Research progress on the predictive value of electrocardiographic indicators in the diagnosis and prognosis of children with vasovagal syncope. *Front Cardiovasc Med*. 2022;9:916770.
124. Yan H, Wang S, Cai H, Zhang J, Liu P, Wang Y, et al. Prognostic value of biomarkers in children and adolescents with orthostatic intolerance. *Front Pediatr*. 2021;9:752123.
125. Cheng W, Wang J, Lin J. Biomarkers and hemodynamic parameters in the diagnosis and treatment of children with postural tachycardia syndrome and vasovagal syncope. *Int J Environ Res Public Health*. 2022;19:6974.
126. McIntyre-Patton L, Wanderski S, Graef D, Woessner L, Baker R. Randomized trial evaluating the effectiveness of a leg crossing and muscle tensing technique on decreasing vasovagal symptoms among pediatric and young adult patients undergoing peripheral IV catheter insertion. *J Pediatr Nurs*. 2018;38:53–6.
127. Liu P, Mei W, Zhou M, Zhao T, Wang Y, Zou R, et al. Application of mind map can promote the health education effect



- of children with vasovagal syncope. *Front Cardiovasc Med.* 2023;10:1051677.
128. Julliard S, Desmarest M, Gonzalez L, Ballesteros Y, Martinez A, Moretti R, et al. Recovery position significantly associated with a reduced admission rate of children with loss of consciousness. *Arch Dis Child.* 2016;101:521–6.
  129. Williams EL, Khan FM, Claydon VE. Counter pressure maneuvers for syncope prevention: a semi-systematic review and meta-analysis. *Front Cardiovasc Med.* 2022;9:1016420.
  130. Wieling W, van Dijk N, Thijs RD, de Lange FJ, Krediet CT, Halliwill JR. Physical countermeasures to increase orthostatic tolerance. *J Intern Med.* 2015;277:69–82.
  131. Jensen JL, Ohshimo S, Cassan P, Meyran D, Greene J, Ng KC, et al. Immediate interventions for presyncope of vasovagal or orthostatic origin: a systematic review. *Prehosp Emerg Care.* 2020;24:64–76.
  132. Anderson JB, Czosok RJ, Knilians TK, Marino BS. The effect of pediatric syncope on health-related quality of life. *Cardiol Young.* 2012;22:583–8.
  133. Zhang Q, Jin H, Wang L, Chen J, Tang C, Du J. Randomized comparison of metoprolol versus conventional treatment in preventing recurrence of vasovagal syncope in children and adolescents. *Med Sci Monit.* 2008;14:CR199–203
  134. Tao C, Li X, Tang C, Jin H, Du J. Acceleration index predicts efficacy of orthostatic training on vasovagal syncope in children. *J Pediatr.* 2019;207:54–8.
  135. Tao CY, Tang CS, Chen S, Jin HF, Du JB. Autonomic nervous function in vasovagal syncope of children and adolescents. *Neurosci Bull.* 2019;35:937–40.
  136. Chun KJ, Yim HR, Park J, Park SJ, Park KM, On YK, et al. Role of baroreflex sensitivity in predicting tilt training response in patients with neurally mediated syncope. *Yonsei Med J.* 2016;57:313–20.
  137. Gu S, Wang S, Wang Y, Liu P, Zhang J, Cai H, et al. Prognosis value of blood pressure variability in children with vasoinhibitory type vasovagal syncope. *Indian J Pediatr.* 2023;90:409–10.
  138. Chang L, Peng L, Liu J, Wang M, Li M, Kong Q, et al. Predictive analysis of catecholamines and electrolytes for recurrence of orthostatic intolerance in children. *Front Pediatr.* 2023;11:1220990.
  139. Subspecialty Group of Cardiology, Chinese Medical Association; Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics; Subspecialty Group of Cardiology, Beijing Medical Association; Society of Pediatrics, Beijing Medical Association. Expert consensus on the treatment of vasovagal syncope and postural tachycardia syndrome in children. *Zhonghua Er Ke Za Zhi.* 2018;56:6–9 (in Chinese).
  140. Song J, Tao C, Chen G, Chen S, Xu W, Du J, et al. Reduced 24-h sodium excretion is associated with a disturbed plasma acylcarnitine profile in vasovagal syncope children: a pilot study. *Front Pediatr.* 2020;8:98.
  141. Wen C, Wang S, Zou R, Wang Y, Tan C, Xu Y, et al. Duration of treatment with oral rehydration salts for vasovagal syncope in children and adolescents. *Turk J Pediatr.* 2020;62:820–5.
  142. Wang Y, Wang Y, Li X, Du J, Zhang H, Jin H, et al. Efficacy of increased salt and water intake on pediatric vasovagal syncope: a meta-analysis based on global published data. *Front Pediatr.* 2021;9:663016.
  143. Du X, Tao C, Li X, Du J, Liao Y, Jin H. Predicting therapeutic efficacy of oral rehydration salts in children with vasovagal syncope. *Front Pediatr.* 2023;11:1164304.
  144. Tao CY, Chen S, Li XY, Tang CS, Du JB, Jin HF. Body mass index is a promising predictor of response to oral rehydration saline in children with vasovagal syncope. *Chin Med J (Engl).* 2020;134:463–8.
  145. Du X, Tao C, Wang Y, Sun Y, Zhang Q, Zhang C, et al. Twenty-four-hour urinary sodium excretion predicts therapeutic effectiveness of oral rehydration saline in pediatric vasovagal syncope. *Children (Basel).* 2022;9:992.
  146. Chu W, Wang C, Wu L, Lin P, Li F, Zou R. Oral rehydration salts: an effective choice for the treatment of children with vasovagal syncope. *Pediatr Cardiol.* 2015;36:867–72.
  147. Li W, Wang S, Liu X, Zou R, Tan C, Wang C. Assessment of efficacy of oral rehydration salts in children with neurally mediated syncope of different hemodynamic patterns. *J Child Neurol.* 2019;34:5–10.
  148. Anderson JB, Willis M, Lancaster H, Leonard K, Thomas C. The evaluation and management of pediatric syncope. *Pediatr Neurol.* 2016;55:6–13.
  149. Zhang QY, Du JB, Tang CS. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. *J Pediatr.* 2006;149:777–80.
  150. Zhang F, Liao Y, Li X, Chen L, Jin H, Du J. The predictive value of flow-mediated vasodilation on therapeutic efficacy of midodrine hydrochloride for vasovagal syncope in children. *Chin J Pract Pediatr.* 2012;27:102–5 (in Chinese).
  151. Li L, Zhao H, Ma X, Jiao F, Lin J. Calcitonin gene-related peptide predicts therapeutic response to midodrine hydrochloride in children with vasovagal syncope. *Front Neurosci.* 2022;16:1026539.
  152. Du X, Li X, Zhang C, Liu P, Wang Y, Zhang Q, et al. Serum uric acid predicts therapeutic response to midodrine hydrochloride in children with vasovagal syncope: a pilot study. *Eur J Pediatr.* 2024;183:371–8.
  153. Chen L, Du JB, Zhang QY, Wang C, Du ZD, Wang HW, et al. A multicenter study on treatment of autonomous nerve-mediated syncope in children with beta-receptor blocker. *Zhonghua Er Ke Za Zhi.* 2007;45:885–8 (in Chinese).
  154. Wang J, Liu X, Jin H, Du J. Markers for predicting the efficacy of beta-blockers in vasovagal syncope management in children: a mini-review. *Front Cardiovasc Med.* 2023;10:1131967.
  155. Kong Q, Yang X, Cai Z, Pan Y, Wang M, Liu M, et al. Twenty-four-hour urine NE level as a predictor of the therapeutic response to metoprolol in children with recurrent vasovagal syncope. *Ir J Med Sci.* 2019;188:1279–87.
  156. Liao Y, Li XY, Zhang YW, Du JB. Meta-analysis of beta-adrenoceptor blockers for the treatment of vasovagal syncope. *Beijing Da Xue Xue Bao Yi Xue Ban.* 2008;40:603–9 (in Chinese).
  157. Tao C, Li X, Tang C, Jin H, Du J. Baroreflex sensitivity predicts response to metoprolol in children with vasovagal syncope: a pilot study. *Front Neurosci.* 2019;13:1329.
  158. Cui YX, Du JB, Jin HF. Baroreflex sensitivity and its implication in neurally mediated syncope in children. *World J Pediatr.* 2023;19:1023–9.
  159. Song J, Li H, Wang Y, Liu P, Li X, Tang C, et al. Left ventricular ejection fraction and fractional shortening are useful for the prediction of the therapeutic response to metoprolol in children with vasovagal syncope. *Pediatr Cardiol.* 2018;39:1366–72.
  160. Yuan P, Li X, Tao C, Du X, Zhang C, Du J, et al. Poincaré plot can be a useful Tool to select potential responders to metoprolol therapy in children with vasovagal syncope. *Int J Gen Med.* 2022;15:2681–93.
  161. Yi S, Kong YH, Kim SJ. Fludrocortisone in pediatric vasovagal syncope: a retrospective, single-center observational study. *J Clin Neurol.* 2021;17:46–51.
  162. Lenk M, Alehan D, Ozme S, Celiker A, Ozer S. The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope—a preliminary report. *Eur J Pediatr.* 1997;156:747–50.
  163. Akella K, Olshansky B, Lakkireddy D, Gopinathannair R. Pacing therapies for vasovagal syncope. *J Atr Fibrillation.* 2020;13:2406.

164. Morillo CA, Brignole M. Pacing for vasovagal syncope: tips for use in practice. *Auton Neurosci*. 2022;241:102998.
165. Paech C, Wagner F, Mensch S, Antonin GR. Cardiac pacing in cardioinhibitory syncope in children. *Congenit Heart Dis*. 2018;13:1064–8.
166. Xu L, Zhao Y, Duan Y, Wang R, Hou J, Wang J, et al. Clinical efficacy of catheter ablation in the treatment of vasovagal syncope. *J Clin Med*. 2022;11:5371.
167. Li H, Shao W, Yu X, Gao L, Yuan Y. Efficacy of catheter ablation in ganglionated plexus for malignant vasovagal syncope children. *Cardiol Young*. 2024. <https://doi.org/10.1017/S1047951124000659>.
168. Li J, Zhang Q, Hao H, Jin H, Du J. Clinical features and management of postural tachycardia syndrome in children: a single-center experience. *Chin Med J (Engl)*. 2014;127:3684–9.
169. Tao CY, Jin HF, Du JB. Management of orthostatic intolerance in children the state of the art. *World J Pediatr*. 2020;16:543–8.
170. Zheng X, Chen Y, Du J. Recent advances in the understanding of the mechanisms underlying postural tachycardia syndrome in children: practical implications for treatment. *Cardiol Young*. 2017;27:413–7.
171. Bai W, Han Z, Chen S, Li H, Song J, Qi J, et al. Serum resistin negatively correlates with clinical severity of postural tachycardia syndrome in children. *Pediatr Cardiol*. 2017;38:1639–44.
172. Bai W, Chen SY, Jin HF, Du JB. Vascular dysfunction of postural tachycardia syndrome in children. *World J Pediatr*. 2018;14:13–7.
173. Cutitta KE, Self M, de la Uz C. Postural orthostatic tachycardia syndrome (POTS) in teens: a guide for behavior change to manage symptoms. *Pac Clin Electrophysiol*. 2019;42:283–6.
174. Lei LY, Chew DS, Sheldon RS, Raj SR. Evaluating and managing postural tachycardia syndrome. *Cleve Clin J Med*. 2019;86:333–44.
175. Chen G, Du J, Jin H, Huang Y. Postural tachycardia syndrome in children and adolescents: pathophysiology and clinical management. *Front Pediatr*. 2020;8:474.
176. Xu WR, Jin HF, Du JB. Pathogenesis and individualized treatment for postural tachycardia syndrome in children. *Chin Med J (Engl)*. 2016;129:2241–5.
177. Liao Y, Du J. Pathophysiology and individualized management of vasovagal syncope and postural tachycardia syndrome in children and adolescents: an update. *Neurosci Bull*. 2020;36:667–81.
178. Zhang Q, Xu B, Du J. Update of individualized treatment strategies for postural orthostatic tachycardia syndrome in children. *Front Neurol*. 2020;11:525.
179. Lu W, Yan H, Wu S, Xu W, Jin H, Du J. Hemocytometric measures predict the efficacy of oral rehydration for children with postural tachycardia syndrome. *J Pediatr*. 2017;187:220–4.
180. Xu B, Gao Y, Zhang Q, Li X, Liu X, Du J, et al. Establishment and validation of a multivariate predictive model for the efficacy of oral rehydration salts in children with postural tachycardia syndrome. *EBioMedicine*. 2024;100:104951.
181. Wang Y, Du J, Li X, Liu P, Wang Y, Liao Y, Jin H. Impact of comorbidities on the prognosis of pediatric postural tachycardia syndrome. *Int J Gen Med*. 2021;14:8945–54.
182. Li J, Zhang Q, Liao Y, Zhang C, Hao H, Du J. The value of acetylcholine receptor antibody in children with postural tachycardia syndrome. *Pediatr Cardiol*. 2015;36:165–70.
183. Lin J, Zhao H, Shen J, Jiao F. Salivary cortisol levels predict therapeutic response to a sleep-promoting method in children with postural tachycardia syndrome. *J Pediatr*. 2017;191:91–5.e1.
184. Bruce BK, Harrison TE, Bee SM, Luedtke CA, Porter CJ, Fischer PR, et al. Improvement in functioning and psychological distress in adolescents with postural orthostatic tachycardia syndrome. *Clin Pediatr (Phila)*. 2016;55:1300–4.
185. Lu W, Yan H, Wu S, Chen S, Xu W, Jin H, et al. Electrocardiography-derived predictors for therapeutic response to treatment in children with postural tachycardia syndrome. *J Pediatr*. 2016;176:128–33.
186. Medow MS, Guber K, Chokshi S, Terilli C, Visintainer P, Stewart JM. The benefits of oral rehydration on orthostatic intolerance in children with postural tachycardia syndrome. *J Pediatr*. 2019;214:96–102.
187. Zhang Q, Liao Y, Tang C, Du J, Jin H. Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. *J Pediatr*. 2012;161:281–4.
188. Li H, Wang Y, Liu P, Chen Y, Feng X, Tang C, et al. Body mass index (BMI) is associated with the therapeutic response to oral rehydration solution in children with postural tachycardia syndrome. *Pediatr Cardiol*. 2016;37:1313–8.
189. Lin J, Liu P, Wang Y, Li H, Li X, Zhao J, et al. Evaluation of the changes in heart rate during head-up test predicting the efficacy of oral rehydration salts on postural tachycardia syndrome in children. *Zhonghua Er Ke Za Zhi*. 2015;53:25–9 (in Chinese).
190. Li H, Liao Y, Wang Y, Liu P, Sun C, Chen Y, et al. Baroreflex sensitivity predicts short-term outcome of postural tachycardia syndrome in children. *PLoS One*. 2016;11:e0167525.
191. Chen L, Wang L, Sun J, Qin J, Tang C, Jin H, et al. Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. *Circ J*. 2011;75:927–31.
192. Zhao J, Tang C, Jin H, Du J. Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children. *J Pediatr*. 2014;165:290–4.e1.
193. Deng WJ, Liu YL, Liu AD, Holmberg L, Ochs T, Li X, et al. Difference between supine and upright blood pressure associates to the efficacy of midodrine on postural orthostatic tachycardia syndrome (POTS) in children. *Pediatr Cardiol*. 2014;35:719–25.
194. Fan S, Cui Y, Liao Y, Jin H. Predicting therapeutic efficacy of pharmacological treatments in children with postural orthostatic tachycardia syndrome: a mini-review. *Children (Basel)*. 2023;10:1093.
195. Lin J, Jin H, Du J. Assessment of therapeutic biomarkers in the treatment of children with postural tachycardia syndrome and vasovagal syncope. *Cardiol Young*. 2014;24:792–6.
196. Liao Y, Yang J, Zhang F, Chen S, Liu X, Zhang Q, et al. Flow-mediated vasodilation as a predictor of therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. *Am J Cardiol*. 2013;112:816–20.
197. Yang J, Zhao J, Du S, Liu D, Fu C, Li X, et al. Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride. *J Pediatr*. 2013;163:1169–73.e2.
198. Li HX, Zheng XC, Chen SY, Liao Y, Han ZH, Huang P, et al. Increased endogenous sulfur dioxide involved in the pathogenesis of postural tachycardia syndrome in children. *Chin Med J (Engl)*. 2018;131:435–9.
199. Zhang FW, Li XY, Ochs T, Chen L, Liao Y, Tang C, et al. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. *J Am Coll Cardiol*. 2012;60:315–20.
200. Yuan P, Lian Z, Wang Y, Zhang C, Jin H, Du J, et al. Poincaré plot can help predict the curative effect of metoprolol for pediatric postural orthostatic tachycardia syndrome. *Front Neurosci*. 2023;17:1280172.
201. Yang J, Liao Y, Zhang F, Chen L, Du J, Jin H. The follow-up study on the treatment of children with postural orthostatic tachycardia syndrome. *Int J Pediatr*. 2014;41:76–9.
202. Deng W, Yang J, Liu Y, Du J, Jin H. A time-effect analysis of postural orthostatic tachycardia syndrome treated with midodrine

- hydrochloride in children. *Chin J Pract Pediatr.* 2013;28:274–6 (in Chinese).
203. Zhao J, Du S, Yang J, Lin J, Tang C, Du J, et al. Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children. *Am J Cardiol.* 2014;114:601–5.
  204. Lin J, Han Z, Li H, Chen SY, Li X, Liu P, et al. Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome. *PLoS One.* 2015;10:e0121913.
  205. Zhang Q, Chen X, Li J, Du J. Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome. *J Transl Med.* 2014;12:249.
  206. Cui Y, Wang Y, Liu P, Wang Y, Du J, Jin H. Baroreflex sensitivity predicts therapeutic effects of metoprolol on pediatric postural orthostatic tachycardia syndrome. *Front Cardiovasc Med.* 2022;9:930994.
  207. Wang Y, Zhang C, Chen S, Liu P, Wang Y, Tang C, et al. Heart rate variability predicts therapeutic response to metoprolol in children with postural tachycardia syndrome. *Front Neurosci.* 2019;13:1214.
  208. Wang Y, Sun Y, Zhang Q, Zhang C, Liu P, Wang Y, et al. Baseline corrected QT interval dispersion is useful to predict effectiveness of metoprolol on pediatric postural tachycardia syndrome. *Front Cardiovasc Med.* 2022;8:808512.
  209. Xu BW, Zhang QY, Li XY, Tang CS, Du JB, Liu XQ, et al. A predictive model of response to metoprolol in children and adolescents with postural tachycardia syndrome. *World J Pediatr.* 2023;19:390–400.
  210. Wang S, Zou R, Cai H, Wang Y, Ding Y, Tan C, et al. Heart rate and heart rate difference predicted the efficacy of metoprolol on postural tachycardia syndrome in children and adolescents. *J Pediatr.* 2020;224:110–4.
  211. Wang S, Zou R, Cai H, Wang C. Prognostic value of heart rate and blood pressure on the prognosis of postural tachycardia syndrome in children. *Front Pediatr.* 2022;10:802469.
  212. Deng X, Zhang Y, Liao Y, Du J. Efficacy of  $\beta$ -blockers on postural tachycardia syndrome in children and adolescents: a systematic review and meta-analysis. *Front Pediatr.* 2019;7:460.
  213. Guven B, Oner T, Tavli V, Yilmazer MM, Demirpence S, Mese T. Low iron storage in children with tilt positive neurally mediated syncope. *World J Pediatr.* 2013;9:146–51.
  214. Blitshteyn S. Vitamin B1 deficiency in patients with postural tachycardia syndrome (POTS). *Neurol Res.* 2017;39:685–8.
  215. Do T, Diamond S, Green C, Warren M. Nutritional implications of patients with dysautonomia and hypermobility syndromes. *Curr Nutr Rep.* 2021;10:324–33.
  216. Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. *CMAJ.* 2022;194:E378–85.
  217. Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. *J Neurol.* 2017;264:1567–82.
  218. Loughlin EA, Judge CS, Gorey SE, Costello MM, Murphy RP, Waters RF, et al. Increased salt intake for orthostatic intolerance syndromes: a systematic review and meta-analysis. *Am J Med.* 2020;133:1471–8.e4.
  219. Raj SR, Coffin ST. Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypotension. *Prog Cardiovasc Dis.* 2013;55:425–33.
  220. Hu Y, Jin H, Du J. Orthostatic hypertension in children: an update. *Front Pediatr.* 2020;8:425.
  221. Gu S, Wang S, Wang Y, Zhang J, Cai H, Zou R, et al. Changes of blood pressure variability in children with postural tachycardia syndrome. *Children (Basel).* 2023;10:1244.
  222. Peng Y, Wang S, Zou R, Cai H, Zhang J, Wang Y, et al. The influence of sex on the treatment of postural tachycardia syndrome in children. *Medicine (Baltimore).* 2023;102:e33951.
  223. Li Y, Li H, Li X, Li X, Jin H. Prognostic analysis of orthostatic intolerance using survival model in children. *Chin Med J (Engl).* 2014;127:3690–4.
  224. Tao C, Xu B, Liao Y, Li X, Jin H, Du J. Predictor of syncopal recurrence in children with vasovagal syncope treated with metoprolol. *Front Pediatr.* 2022;10:870939.
  225. Sun R, Kang Y, Zhang M, Wang H, Shi L, Li X. Development of prognostic nomogram model to predict syncope recurrence in children with vasovagal syncope. *Front Cardiovasc Med.* 2023;10:1099115.
  226. Sun R, Kang Y, Zhang M, Wang H, Shi L, Li X. Development of a nomogram model to predict malignant vasovagal syncope in Chinese children. *Front Pediatr.* 2023;11:1158537.
  227. Song JY, Li HX, Li XY, Wang YL, Jin HF, Du JB. Relationship between blood routine test parameters and syncopal recurrence of vasovagal syncope in children. *Zhonghua Er Ke Za Zhi.* 2017;55:59–63 (in Chinese).
  228. Tao C, Lu W, Lin J, Li H, Li X, Tang C, et al. Long-term outcomes of children and adolescents with postural tachycardia syndrome after conventional treatment. *Front Pediatr.* 2019;7:261.
  229. Li H, Zhang F, Wang Y, Liu P, Zhang C, Feng X, et al. Predictive value of baseline plasma midregional fragment of pro-adrenomedullin level on long-term outcome of postural tachycardia syndrome children treated with midodrine hydrochloride. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2015;43:507–10 (in Chinese).
  230. Bhatia R, Kizilbash SJ, Ahrens SP, Killian JM, Kimmes SA, Knoebel EE, et al. Outcomes of adolescent-onset postural orthostatic tachycardia syndrome. *J Pediatr.* 2016;173:149–53.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Cheng Wang<sup>1</sup> · Ying Liao<sup>2</sup> · Shuo Wang<sup>3</sup> · Hong Tian<sup>4</sup> · Min Huang<sup>5</sup> · Xiang-Yu Dong<sup>6</sup> · Lin Shi<sup>7</sup> · Ya-Qi Li<sup>7</sup> · Jing-Hui Sun<sup>8</sup> · Jun-Bao Du<sup>2</sup> · Hong-Fang Jin<sup>2,9</sup> · Chinese Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association; Committee of Pediatric Syncope, College of Pediatricians, Chinese Medical Doctor Association; Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association; Committee of Pediatric Cardiology, College of Cardiovascular Physicians, Chinese Medical Doctor Association

✉ Jun-Bao Du  
junbaodu1@126.com

✉ Hong-Fang Jin  
jinhongfang51@126.com

<sup>1</sup> Department of Pediatric Cardiovasology, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha 410011, China

<sup>2</sup> Department of Pediatrics, Peking University First Hospital, Beijing 100034, China

<sup>3</sup> Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China

<sup>4</sup> Department of Pediatric Cardiology, Children's Hospital of Fudan University, Shanghai 201102, China

<sup>5</sup> Department of Pediatric Cardiology, Shanghai Children's Hospital, Shanghai 201102, China

<sup>6</sup> Department of Pediatrics, Lanzhou University Second Hospital, Lanzhou 730020, China

<sup>7</sup> Department of Pediatric Cardiology, Capital Institute of Pediatrics, Beijing 100020, China

<sup>8</sup> Department of Pediatrics, Jilin University First Hospital, Changchun 130021, China

<sup>9</sup> State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China